Supporting Information for:

A Multifaceted Approach Towards Understanding the Peculiar Behavior of α-Hydroxyiminophosphonates

Thomas Toupy,^a Christopher Kune,^b Kristof Van Hecke,^c Loïc Quinton,^b and Jean-Christophe M. Monbaliu^{*,a}

^aCenter for Integrated Technology and Organic Synthesis, MolSys Research Unit, University of Liège, B-4000 Liège (Sart Tilman), Belgium

^bMass Spectrometry Laboratory, MolSys Research Unit, University of Liège, B-4000 Liège (Sart Tilman), Belgium

°XStruct, Department of Chemistry, Ghent University, Krigslaan 281-S3, B-9000 Ghent, Belgium

Table of Contents

1.	Addi	tiona	l experimental details5
1	L.1	Che	micals5
2	2.1	Add	itional experimental data7
	2.1.1	P	rocedures for the synthesis of acyl chlorides:7
	2.1.1	.1	Batch procedure for the synthesis of 2-(phenylthio)acetyl chloride (ac-15) ¹ 7
	2.1.1	.2	Batch procedure for the synthesis of 2-(1 <i>H</i> -indol-3-yl)acetyl chloride (ac-16) ² 7
	2.1.2	G	ieneral procedure for the synthesis of $lpha$ -keto-phosphonates (1a – 16a)7
	2.1.2 (iso- 3	.1 3a) ³	Batch procedure for the synthesis of diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate 7
	2.1.2	.2	Batch procedure for the synthesis of dimethyl isobutyrylphosphonate (4a) ⁴ 7
	2.1.2	.3	Batch procedure for the synthesis of diethyl isobutyrylphosphonate (5a) ⁵ 8
	2.1.2	.4	Batch procedure for the synthesis of dimethyl (3-methylbutanoyl)phosphonate $(7a)^6$ 8
	2.1.2	.5	Batch procedure for the synthesis of diethyl (3-methylbutanoyl)phosphonate (8a) ⁷ 8
	2.1.2 meth	.6 юхур	Batch procedure for the synthesis of diethyl (1-hydroxy-2-(4- henyl)vinyl)phosphonate (iso-13a) ⁵ 8
	2.1.3	Р	rocedures for the synthesis of $lpha$ -hydroxyiminophosphonates (oximes)8
	2.1.3	.1	General batch procedure for the preparation of α -hydroxyiminophosphonates (1b – 16b)8
	2.1.3 phen	.2 yleth	Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-2- yl)phosphonate (1b) ⁸
	2.1.3 (2b) ⁹	.3	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate 9
	2.1.3 phen	.4 yleth	Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-2- yl)phosphonate (3b)

2.1.3.5	Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-2-
methylpro	pyl)phosphonate (4b)9
2.1.3.6	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-
methylpro	pyl)phosphonate (5b) ¹⁰ 10
2.1.3.7	Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-2-
methylproj	pyl)phosphonate (6b)
2.1.3.8	Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-3-
methylbuty	yl)phosphonate (7b) ⁸ 10
2.1.3.9 (8b) ¹⁰	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate 10
2.1.3.10	Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-3-
methylbuty	yl)phosphonate (9b)11
2.1.3.11	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)ethyl)phosphonate (10b) ¹¹ 11
2.1.3.12	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2,2-
dimethylpr	opyl)phosphonate (11b) ¹² 11
2.1.3.13 (12b)	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate 12
2.1.3.14	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-(4-
methoxypł	nenyl)ethyl)phosphonate (13b) ¹³ 12
2.1.3.15	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-3-
(methylthio	o)propyl)phosphonate (14b) ¹⁰ 12
2.1.3.16	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-
(phenylthio	b)ethyl)phosphonate (15b)12
2.1.3.17	Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-(1 <i>H</i> -indol-3-
yl)ethyl)ph	osphonate (16b) ² 13
2.1.4 Pr	ocedures for the synthesis of $lpha$ -hydroxyaminophosphonates (hydroxylamines)13
2.1.4.1	General batch procedure for the final reduction step towards α -
hydroxyam	ninophosphonates (1c – 16c)13
2.1.4.2	Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-2-
phenylethy	/l)phosphonate (1c)
2.1.4.3 (2c) ¹⁴	Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate 14
2.1.4.4	Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-2-
phenylethy	/l)phosphonate (3c)14
2.1.4.5	Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-2-
methylpro	pyl)phosphonate (4c) ¹⁵ 14
2.1.4.6	Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-
methylproj	pyl)phosphonate (5c) ¹⁶ 15
2.1.4.7	Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-2-
methylproj	pyl)phosphonate (6c)15
2.1.4.8	Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-3-
methylbuty	yl)phosphonate (7c)15

	2.1.4 meth	9.9 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-3- hylbutyl)phosphonate (8c)	
	2.1.4 meth	1.10 Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-3- hylbutyl)phosphonate (9c)	16
	2.1.4	Batch procedure for the synthesis of diethyl (1-(hydroxyamino)ethyl)phosphonate (1	L Oc) 16
	2.1.4 dime	1.12 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2,2- hthylpropyl)phosphonate (11c)	17
	2.1.4 meth	1.13 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2- hylbutyl)phosphonate (12c)	17
	2.1.4 meth	1.14 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-(4- hoxyphenyl)ethyl)phosphonate (13c)	17
	2.1.4 (metl	1.15 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-3- hylthio)propyl)phosphonate (14c)	
	2.1.4 (pher	1.16 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2- nylthio)ethyl)phosphonate (15c)	
	2.1.4 yl)etł	17 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-(1 <i>H</i> -indol-3- hyl)phosphonate (16c)	
	2.1.5	Batch procedure for the synthesis of diethyl (1-amino-2-phenylethyl)phosphonate (am	-2b) ⁹ 19
	2.1.6	Batch procedure for the synthesis of 4 N HCl in MeOH ¹⁷	19
Ĩ	2.2	Characterization of compounds	20
-	2.3	LC analysis	29
	2.3.1	Analytical Method	29
	2.3.2	Copies of representative LC traces	
	2.4	Copies of ¹ H, ¹³ C and ³¹ P NMR spectra	32
-	2.5	Copies of IR spectra	92
Ĩ	2.6	Molecular structure by single crystal X-ray diffraction analysis of compounds 2b and 3b	95
3	Collis	sion energy breakdown curves and survival yields	97
	3.1	Dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1b)	97
3	3.2	Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b)	99
	3.3	Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3b)	101
	3.4	Dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (4b)	103
3	3.5	Diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b)	105
3	3.6	Diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (6b)	107
3	3.7	Dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b)	109
	3.8	Diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b)	111
3	3.9	Diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (9b)	113
3	3.10	Diethyl (1-(hydroxyimino)ethyl)phosphonate (10b)	115
	3.11	Diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (11b)	116
3	3.12	Diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b)	118

3.13	Diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (13b)	120
3.14	Diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (14b)	122
3.15	Diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (15b)	124
3.16	Diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (16b)	126
4 Com	putational study	135
4.1	Oxime isomers	135
4.1.	1 Protonation site with regards to the isomers	135
5 Refe	erences	136

1. Additional experimental details

1.1 Chemicals

Chemicals, purity, CAS numbers and suppliers are provided in Table S1.

Table S1. Solvents, chemicals and suppliers

Solvents	Purity (%)	CAS Number	Supplier
THF	99.8	109-99-9	Fisher
Diethyl ether	>99	60-29-7	VWR
Ethanol (absolute)	>99	64-17-5	VWR
Hexane	98.5	110-54-3	VWR
Ethyl acetate	≥99.5	141-78-6	Aldrich
Methanol	>99	67-56-1	VWR
Petroleum ether (40-60)	>99	8032-32-4	VWR
Chloroform	>99.8	67-66-3	Fisher
Dichloromethane	>99.8	75-09-2	Fisher
Dimethylformamide	99	68-12-2	VWR

Chemicals	Purity (%)	CAS number	Supplier
Acetic acid (glacial)	≥ 99	64-19-7	VWR
Hydroxylamine hydrochloride	97	5470-11-1	ТСІ
Pyridine	99	110-86-1	ТСІ
Sodium bicarbonate	99	144-55-8	Sigma Aldrich
Triethyl phosphite	98	122-52-1	Sigma Aldrich
Trimethyl phosphite	97	121-45-9	Alfa Aesar
Triisopropyl phosphite	96	116-17-6	ACROS ORGANICS
Acetyl chloride	98	75-36-5	Sigma Aldrich
Phenylacetyl chloride	>98	103-80-0	ТСІ
Isovaleryl chloride	>99	108-12-3	ТСІ
4-Methoxyphenylacetyl chloride	98	4693-91-8	Alfa Aesar

3-(Methylthio)propionyl chloride	>98	7031-23-4	TCI
Isobutyryl chloride	>98	79-30-1	ТСІ
DL-2-Methylbutyryl chloride	98	57526-28-0	ACROS ORGANICS
3-Indoleacetic acid	>98	87-51-4	TCI
(Phenylthio)acetic acid	>98	103-04-8	TCI
Trimethylacetyl chloride	99	3282-30-2	Sigma Aldrich
Thionyl chloride	97	7719-09-7	Sigma Aldrich
Oxalyl chloride	98	79-37-8	Sigma Aldrich
Sodium cyanoborohydride	95	25895-60-7	ACROS ORGANICS
Sodium borohydride	95	16940-66-2	TCI
Borane pyridine complex	n.a.	110-51-0	Sigma Aldrich
Zinc dust	98	7440-66-6	Sigma Aldrich
Hydrogen chloride (2 N in Et ₂ O)	n.a.	7647-01-0	Sigma Aldrich

2.1 Additional experimental data

2.1.1 Procedures for the synthesis of acyl chlorides:

2.1.1.1 Batch procedure for the synthesis of 2-(phenylthio)acetyl chloride (ac-15)¹



A mixture of thiophenoxyacetic acid (20.0 g, 118.90 mmol, 1 eq.) and $SOCI_2$ (21.56 mL, 297.20 mmol, 2.5 eq.) was refluxed (80°C) for 1h. The excess $SOCI_2$ was removed *in vacuo* (under a well ventilated fume <u>hood</u>) and the residual orange oil was purified by distillation to afford 2-(phenylthio)acetyl chloride (17.8 g, 80 %) as a yellow liquid; bp 162-166 °C/5 mbar.

2.1.1.2 Batch procedure for the synthesis of 2-(1*H*-indol-3-yl)acetyl chloride (ac-16)²



C₁₀H₈CINO

MW193.63

Oxalyl chloride (2.7 mL, 31.40 mmol, 1.1 eq.) was added dropwise over 15 min to a stirred solution of indole-3-acetic acid (5.0 g, 28.55 mmol, 1 eq.) in 100 mL of dry dichloromethane under an argon atmosphere. The mixture was stirred at 0 °C for 5 min and then DMF (0.11 mL, 1.42 mmol, 0.05 eq.) was added in one portion. The solution was warmed at room temperature and then stirred

until the evolution of gas ceased (roughly 30 min). The mixture was then concentrated under reduced pressure to leave the corresponding acyl chloride as an orange oil, which was used as is in the next step.

2.1.2 General procedure for the synthesis of α -keto-phosphonates (**1a – 16a**)

In a 250 mL flamed-dried round-bottomed flask was added the starting acyl chloride (100 mmol, 1 eq.) in 100 mL of dry diethyl ether. The mixture was then cooled down to 0 °C in an ice bath and the corresponding trialkylphosphite ($P(OMe)_3$, $P(OEt)_3$ or $P(OPr)_3$; 100 mmol, 1 eq.) was slowly added over 1 h using a syringe pump. Upon addition, the solution was heated to room temperature and left stirring overnight. The solvent was then evaporated under reduced pressure and the remaining product was either purified by recrystallisation (**iso-3a**), distillation under vacuum (**4a**, **5a**, **7a**, **8a**), or used as is in the next step. Typical yields ranged from 62 to 97%

2.1.2.1 Batch procedure for the synthesis of diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate



(iso-3a)³

After evaporation of the solvent under reduced pressure, the crude oil was purified by recrystallization in hot hexane/ethyl acetate to yield the desired diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate (enol form) (19.67 g, 69%) as white crystals; mp 81-84 °C.

2.1.2.2 Batch procedure for the synthesis of dimethyl isobutyrylphosphonate (4a)⁴



After evaporation of the solvent under reduced pressure, the crude oil was purified by distillation under vacuum to afford dimethyl isobutyrylphosphonate (ketone form) (14.20 g, 79%) as a transparent oil; bp 140-142°C/10mbar.



2.1.2.3 Batch procedure for the synthesis of diethyl isobutyrylphosphonate (**5a**)⁵ After evaporation of the solvent under reduced pressure, the crude oil was purified by distillation under vacuum to afford diethyl isobutyrylphosphonate (ketone form) (15.76 g, 76%) as a transparent oil; bp 144-150°C/10mbar. 2.1.2.4 Batch procedure for the synthesis of dimethyl (3-methylbutanoyl)phosphonate (7a)⁶



After evaporation of the solvent under reduced pressure, the crude oil was purified by distillation under vacuum to afford dimethyl (3-methylbutanoyl)phosphonate (ketone form) (12.10 g, 62%) as a transparent oil; bp 148-152°C/10mbar.

2.1.2.5 Batch procedure for the synthesis of diethyl (3-methylbutanoyl)phosphonate (8a)⁷



After evaporation of the solvent under reduced pressure, the crude oil was purified by distillation under vacuum to afford diethyl (3-methylbutanoyl)phosphonate (ketone form) (14.61 g, 66%) as a transparent oil; bp 150-154°C/10mbar.

2.1.2.6 Batch procedure for the synthesis of diethyl (1-hydroxy-2-(4methoxyphenyl)vinyl)phosphonate (**iso-13a**)⁵



After evaporation of the solvent under reduced pressure we obtained
 the desired diethyl (1-hydroxy-2-(4-methoxyphenyl)vinyl)phosphonate
 (enol form) (18.34 g, 64%) as an off-white powder.

2.1.3 Procedures for the synthesis of α -hydroxyiminophosphonates (oximes)

2.1.3.1 General batch procedure for the preparation of α -hydroxyiminophosphonates (**1b** – **16b**) The corresponding (α) -ketophosphonate intermediate (1 eq.) was added to a solution of hydroxylamine hydrochloride (1.2 eq.) in dry pyridine (2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL), washed with 3 N HCl (3 \times 50 mL) and water (50 mL). the organic layer was dried with anhydrous filtered and concentrated in vacuo to provide the desired Na₂SO₄. (α)hydroxyiminophosphonate as a mixture of two isomers (E/Z). In some cases, further purification by recrystallization (2b,16b) or column purification (11b, 12b, 14b, 15b) was required to reach high purity. Typical yields ranged from 45 to 92%.

2.1.3.2 Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-2phenylethyl)phosphonate (**1b**)⁸



Dimethyl (2-phenylacetyl)phosphonate (2.5 g, 11.13 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (0.9 g, 13.36 mmol, 1.2 eq.) in dry pyridine (1.9 g, 24.49 mmol, 2.2 eq.) and absolute ethanol (20 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in

ethyl acetate (50 mL), washed with 3 N HCl (3 × 40 mL) and water (40 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1.7 g, 63% isolated yield) as a mixture of two isomers (*E/Z*, 47.4/52.6) (transparent oil).

2.1.3.3 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b)⁹



Diethyl (2-phenylacetyl)phosphonate (4.0 g, 15.61 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.3 g, 18.73 mmol, 1.2 eq.) in dry pyridine (2.7 g, 34.34 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in

dichloromethane (70 mL), washed with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residual sluggish oil was recrystallized from cyclohexane:EtOH to provide the desired diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2.8 g, 66% isolated yield) as a mixture of two isomers (*E/Z*, 71.4/28.6) (white crystals; mp 49-52 °C).

2.1.3.4 Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-2phenylethyl)phosphonate (**3b**)



Diisopropyl (2-phenylacetyl)phosphonate (4.0 g, 14.07 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.2 g, 16.88 mmol, 1.2 eq.) in dry pyridine (2.4 g, 30.95 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in

dichloromethane (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Upon evaporation of the residual solvent, the oily residue solidified to yield the desired diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3.4 g, 81% isolated yield) as a mixture of two isomers (*E*/*Z*, 95.2/4.8) (white solid). Recrystallization of the crude solid in boiling EtOH enabled to obtain the product as the sole *E* isomer (white crystals; mp 94-97 °C).

2.1.3.5 Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-2methylpropyl)phosphonate (**4b**)



Dimethyl isobutyrylphosphonate (5.0 g, 27.75 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (2.3 g, 33.31 mmol, 1.2 eq.) in dry pyridine (4.8 g, 61.06 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL), washed

with 3 N HCl (3 × 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (3.6 g, 66% isolated yield) as a mixture of two isomers (E/Z, 45.7/54.3) (white solid).

2.1.3.6 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2methylpropyl)phosphonate (**5b**)¹⁰



Diethyl isobutyrylphosphonate (6.0 g, 28.82 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (2.4 g, 34.58 mmol, 1.2 eq.) in dry pyridine (5.0 g, 63.40 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5.2 g, 81% isolated yield) as a mixture of two isomers (E/Z, 52.6/47.4) (white solid).

2.1.3.7 Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-2methylpropyl)phosphonate (**6b**)

O V OⁱPr OⁱPr OⁱPr NOH C₁₀H₂₂NO₄P MW 251,26

Diisopropyl isobutyrylphosphonate (7.0 g, 29.63 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (2.5 g, 35.55 mmol, 1.2 eq.) in dry pyridine (5.2 g, 65.18 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL), washed

with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (6.6 g, 88% isolated yield) as a mixture of two isomers (*E*/*Z*, 73.5/26.5) (white solid).

2.1.3.8 Batch procedure for the synthesis of dimethyl (1-(hydroxyimino)-3methylbutyl)phosphonate (**7b**)⁸



Dimethyl (3-methylbutanoyl)phosphonate (4.0 g, 20.60 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.7 g, 24.72 mmol, 1.2 eq.) in dry pyridine (3.6 g, 45.32 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL),

washed with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (3.1 g, 71% isolated yield) as a mixture of two isomers (*E/Z*, 39.8/60.2) (transparent oil).

2.1.3.9 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b)¹⁰



Diethyl (3-methylbutanoyl)phosphonate (8.9 g, 40.0 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (3.3 g, 48.0 mmol, 1.2 eq.) in dry pyridine (6.9 g, 88.0 mmol, 2.2 eq.) and absolute ethanol (50 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL),

washed with 3 N HCl (3 \times 60 mL) and water (60 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7.2 g, 76% isolated yield) as a mixture of two isomers (*E/Z*, 50.5/49.5) (transparent oil).

2.1.3.10 Batch procedure for the synthesis of diisopropyl (1-(hydroxyimino)-3methylbutyl)phosphonate (**9b**)



Diisopropyl (3-methylbutanoyl)phosphonate (4.0 g, 15.98 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.3 g, 19.20 mmol, 1.2 eq.) in dry pyridine (2.8 g, 35.16 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in

dichloromethane (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (3.9 g, 92% isolated yield) as a mixture of two isomers (*E/Z*, 58.5/41.5) (transparent oil).

2.1.3.11 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)ethyl)phosphonate (**10b**)¹¹



Diethyl acetylphosphonate (4.0 g, 22.21 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.8 g, 26.65 mmol, 1.2 eq.) in dry pyridine (3.8 g, 48.84 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL), washed with 3 N HCl (3×50 mL)

and water (50 mL). The organic layer was dried with anhydrous Na_2SO_4 , filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyimino)ethyl)phosphonate (3.6 g, 83% isolated yield) as a mixture of two isomers (*E*/*Z*, 98.0/2.0) (transparent oil).

2.1.3.12 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2,2dimethylpropyl)phosphonate (**11b**)¹²



Diethyl pivaloylphosphonate (5.0 g, 22.50 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.9 g, 27.00 mmol, 1.2 eq.) in dry pyridine (3.9 g, 49.50 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The

crude product was dissolved in ethyl acetate (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residual oil was purified by column chromatography using 70:30 (v:v) EtOAc:petroleum ether (40-60) to provide the desired diethyl (1-(hydroxyimino)-2,2-(dimethylpropyl)phosphonate (Rf = 0.49) (3.2 g, 60% isolated yield) as a mixture of two isomers (*E/Z*, 58.5/41.5) (transparent oil).

2.1.3.13 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2methylbutyl)phosphonate (**12b**)



Diethyl (2-methylbutanoyl)phosphonate (5.0 g, 22.50 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.9 g, 27.00 mmol, 1.2 eq.) in dry pyridine (3.9 g, 49.50 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (70 mL),

washed with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous

 Na_2SO_4 , filtered and concentrated *in vacuo*. The residual oil was purified by column chromatography using 90:10 (v:v) EtOAc:petroleum ether (40-60) to provide the desired diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (Rf = 0.61) (3.3 g, 62% isolated yield) as a mixture of two isomers (*E/Z*, 29.6/70.4) (transparent oil).

2.1.3.14 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-(4methoxyphenyl)ethyl)phosphonate (**13b**)¹³



Diethyl (2-(4-methoxyphenyl)acetyl)phosphonate (7.0 g, 24.45 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (2.0 g, 29.34 mmol, 1.2 eq.) in dry pyridine (4.2 g, 53.80 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude

product was dissolved in dichloromethane (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (5.8 g, 79% isolated yield) as a mixture of two isomers (*E/Z*, 71.9/28.1) (transparent oil).

2.1.3.15 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**)¹⁰



Diethyl (3-(methylthio)propanoyl)phosphonate (5.0 g, 20.81 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.7 g, 24.97 mmol, 1.2 eq.) in dry pyridine (3.6 g, 45.78 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was dissolved in

dichloromethane (70 mL), washed with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residual oil was purified by column chromatography using 60:40 (v:v) EtOAc:petroleum ether (40-60) to provide the desired diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (Rf = 0.40) (2.8 g, 53% isolated yield) as a mixture of two isomers (*E/Z*, 94.3/5.7) (transparent oil).

2.1.3.16 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**)



Diethyl (2-(phenylthio)acetyl)phosphonate (6.0 g, 21.05 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (1.7 g, 25.26 mmol, 1.2 eq.) in dry pyridine (3.6 g, 46.32 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product was

dissolved in dichloromethane (70 mL), washed with 3 N HCl (3 \times 50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residual oil was purified by column chromatography using 70:30 (v:v) EtOAc:petroleum ether (40-60) to provide the desired diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (Rf = 0.30) (2.9 g, 45% isolated yield) as a mixture of two isomers (*E/Z*, 68.9/31.1) (transparent oil).

2.1.3.17 Batch procedure for the synthesis of diethyl (1-(hydroxyimino)-2-(1*H*-indol-3yl)ethyl)phosphonate (**16b**)²



The crude diethyl (2-(1*H*-indol-3-yl)acetyl)phosphonate (8.4 g, 28.55 mmol, 1 eq.) was added to a solution of hydroxylamine hydrochloride (2.4 g, 34.26 mmol, 1.2 eq.) in dry pyridine (4.9 g, 62.81 mmol, 2.2 eq.) and absolute ethanol (30 mL). The reaction mixture was stirred at room temperature for 12 h and then concentrated under reduced pressure. The crude product

was dissolved in dichloromethane (70 mL), washed with 3 N HCl (3×50 mL) and water (50 mL). The organic layer was dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. The residual brown sluggish oil was dissolved in cold dichloromethane and left in the fridge (+ 4 °C) overnight. The next morning, an off-white powder was filtered and dried under vacuum to provide the desired diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (2.2 g, 25% isolated yield over 3 steps) as a mixture of two isomers (*E/Z*, 45.3/54.7) (off-white powder).

2.1.4 Procedures for the synthesis of α -hydroxyaminophosphonates (hydroxylamines)

2.1.4.1 General batch procedure for the final reduction step towards α -hydroxyaminophosphonates (**1c – 16c**)

The corresponding (α)-hydroxyiminophosphonate intermediate (1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired final (α)-hydroxyaminophosphonate derivative. Typical yields ranged from 1 to 46%.

2.1.4.2 Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-2phenylethyl)phosphonate (**1c**)



Dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3.65 g, 15.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The

reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (0.75 g, 20% isolated yield) as a yellow oil.

2.1.4.3 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (2c)¹⁴



Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1.20 g, 4.42 mmol, 1 eq.) was dissolved in absolute ethanol (10 mL). Sodium cyanoborohydride (0.83 g, 13.26 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (3 mL). The reaction mixture

was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (50 mL) and washed with 3 N HCl (5 × 20 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 20 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (0.31 g, 25% isolated yield) as a pink oil.

2.1.4.4 Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-2phenylethyl)phosphonate (**3c**)



Diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1.83 g, 6.11 mmol, 1 eq.) was dissolved in absolute ethanol (15 mL). Sodium cyanoborohydride (1.15 g, 18.34 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to $pH \sim 3$ by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL).

The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (50 mL) and washed with 3 N HCl (5×20 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4×20 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diisopropyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (0.03 g, 1% isolated yield) as a pink oil.

2.1.4.5 Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-2methylpropyl)phosphonate (**4c**)¹⁵



Dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (2.45 g, 12.55 mmol, 1
 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.36 g, 37.66 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred

overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (0.35 g, 14% isolated yield) as a colorless oil.

2.1.4.6 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2methylpropyl)phosphonate (5c)¹⁶



Diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (3.35 g, 15.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (1.54 g, 46% isolated yield) as a pink oil.

2.1.4.7 Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-2methylpropyl)phosphonate (**6c**)



Diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (3.77 g, 15.00 mmol, 1
eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition of

^{MWV 253,28} freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diisopropyl (1-(hydroxyamino)-2methylpropyl)phosphonate (0.98 g, 26% isolated yield) as a pink oil.

2.1.4.8 Batch procedure for the synthesis of dimethyl (1-(hydroxyamino)-3methylbutyl)phosphonate (**7c**)



Dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (2.80 g, 13.38 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.52 g, 40.15 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred

overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired dimethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (1.19 g, 42% isolated yield) as a pink oil.

2.1.4.9 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-3methylbutyl)phosphonate (8c)



Diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (3.56 g, 15.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred

overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted

with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (1.21 g, 33% isolated yield) as a pink oil.

2.1.4.10 Batch procedure for the synthesis of diisopropyl (1-(hydroxyamino)-3methylbutyl)phosphonate (**9c**)



Diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (3.58 g, 13.50 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.54 g, 40.50 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition

MW 267,31 of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diisopropyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (0.36 g, 10% isolated yield) as a pink oil.

2.1.4.11 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)ethyl)phosphonate (**10c**)



Diethyl (1-(hydroxyimino)ethyl)phosphonate (2.93 g, 15.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL). The reaction mixture was stirred overnight at room temperature and

then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na_2CO_3 and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na_2SO_4 , filtered and concentrated *in vacuo*. The residual oil was triturated with 15 mL of 2 N HCl in Et₂O, the ethereal phase was then discarded to provide the desired diethyl (1-(hydroxyamino)ethyl)phosphonate (0.09 g, 2% isolated yield) as the hydrochloride salt (white powder).

2.1.4.12 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2,2dimethylpropyl)phosphonate (**11c**)



Diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (4.74 g, 20.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (3.77 g, 60.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (6 mL). The reaction mixture was stirred overnight at

room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-2,2-dimethylpropyl)phosphonate (0.91 g, 19% isolated yield) as a pink oil.

2.1.4.13 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2methylbutyl)phosphonate (**12c**)



Diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (4.74 g, 20.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (3.77 g, 60.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH ~ 3 by dropwise addition of freshly prepared 4 N HCl in methanol (6 mL). The reaction mixture was stirred

overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 \times 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide diasteroisomers of the desired diethyl (1-(hydroxyamino)-2-methylbutyl)phosphonate (0.79 g, 17% isolated yield) as a pink oil.

2.1.4.14 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-(4methoxyphenyl)ethyl)phosphonate (**13c**)



Diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (1.00 g, 3.32 mmol, 1 eq.) was dissolved in absolute ethanol (10 mL). Sodium cyanoborohydride (0.62 g, 9.96 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N

HCl in methanol (3 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (50 mL) and washed with 3 N HCl (5 \times 20 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 \times 20 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-2-(4-methoxyphenyl)ethyl)phosphonate (0.26 g, 26% isolated yield) as a pink oil.

2.1.4.15 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate (**14c**)



Diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (3.83 g, 15.00 mmol, 1 eq.) was dissolved in absolute ethanol (20 mL). Sodium cyanoborohydride (2.83 g, 45.00 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to $pH \sim 3$ by dropwise addition of freshly prepared 4 N HCl in methanol (4 mL).

Diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (1.07 g, 3.53

mmol, 1 eq.) was dissolved in absolute ethanol (10 mL). Sodium

The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (100 mL) and washed with 3 N HCl (5 × 30 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane (4 × 30 mL). The combined organic layers were dried with anhydrous Na₂SO₄, filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate (0.15 g, 4% isolated yield) as a pink oil.

2.1.4.16 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-(phenylthio)ethyl)phosphonate (**15c**)

.OEt OEt NHOH C₁₂H₂₀NO₄PS MW 305,33

cyanoborohydride (0.66 g, 10.58 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to $pH \sim 3$ by dropwise addition of freshly prepared 4 N HCl in methanol (3 mL). The reaction mixture was stirred overnight at room temperature and then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (50 mL) and washed with 3 N HCl (5 \times 20 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na₂CO₃ and extracted with dichloromethane $(4 \times 20 \text{ mL})$. The combined organic layers were dried with anhydrous Na₂SO₄, filtered and provide desired diethyl (1-(hydroxyamino)-2concentrated in vacuo to the (phenylthio)ethyl)phosphonate (0.15 g, 14% isolated yield) as a pink oil.

2.1.4.17 Batch procedure for the synthesis of diethyl (1-(hydroxyamino)-2-(1*H*-indol-3yl)ethyl)phosphonate (**16c**)



Diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (0.50 g, 1.60 mmol, 1 eq.) was dissolved in absolute ethanol (10 mL). Sodium cyanoborohydride (0.30 g, 4.83 mmol, 3 eq.) was then added to the reaction mixture in small portions and the pH of the solution was decreased down to pH \sim 3 by dropwise addition of freshly prepared 4 N HCl in methanol (3 mL). The reaction mixture was stirred overnight at room temperature and

then concentrated under reduced pressure. The crude product was dissolved in dichloromethane (50 mL) and washed with 3 N HCl (5 × 20 mL). The pH of the combined aqueous layers was adjusted to 8 with the slow addition of solid Na_2CO_3 and extracted with dichloromethane (4 × 20 mL). The combined organic layers were dried with anhydrous Na_2SO_4 , filtered and concentrated *in vacuo* to provide the desired diethyl (1-(hydroxyamino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (0.08 g, 16% isolated yield) as a pink oil.

2.1.5 Batch procedure for the synthesis of diethyl (1-amino-2-phenylethyl)phosphonate (am-2b)⁹



Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (6.32 g, 23.3 mmol, 1 eq.) was dissolved in 120 mL of a 2:1 (v/v) 1M HCl/Glacial HOAc mixture. To the resulting solution was added active zinc powder (18.31 g, 280 mmol, 12 eq.). After purging with N₂, the mixture was stirred overnight at room temperature. After filtration, the filtrate was concentrated in vacuo to afford a residue, which was washed with Et₂O (3 × 50 mL). The pH of the aqueous

layer was then adjusted to 10 with the slow addition of solid Na_2CO_3 and extracted with dichloromethane (5 × 40 mL). The combined organic phases were then dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give the desired diethyl (1-amino-2-phenylethyl)phosphonate (4.25 g, 71% isolated yield) as a yellowish oil.

2.1.6 Batch procedure for the synthesis of 4 N HCl in MeOH¹⁷ For the preparation of 100 mL of 4 N HCl in MeOH:

In a 250 mL round-bottomed flask, 28.4 mL of acetyl chloride was added dropwise to 71.6 mL of methanol in an ice bath and stirred at 0 °C for 10 min. The reaction medium was then heated to room temperature and the solution was used immediately while fresh.

2.2 Characterization of compounds





C₉H₁₉O₄P MW 222,22

2-(phenylthio)acetyl chloride. (ac-15) ¹H NMR (CDCl₃, 400 MHz): δ = 7.50-7.44 (m, 2H), 7.39-7.29 (m, 3H), 4.06 (s, 2H) ppm. ¹³C (CDCl₃, 100.6 MHz): δ = 131.4, 129.4, 128.2, 48.4 ppm. ESI HRMS *m/z* C₈H₇ClOS⁺ [M+H]⁺: calcd 186.9978; found 186.9981.

Diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate. (iso-3a) ¹H NMR (CDCl₃, 400 MHz): δ = 7.74 (d, *J* = 7.1 Hz, 2H), 7.38 – 7.19 (m, 3H), 6.08 (d, *J* = 12.5 Hz, 1H), 4.83 – 4.68 (m, 2H), 1.40 (d, *J* = 6.2 Hz, 6H), 1.35 (d, *J* = 6.3 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 143.3 (d, *J*_{C-P} = 203.8 Hz), 134.8 (d, *J*_{C-P} = 17.6 Hz), 129.6, 128.4, 127.5, 115.7 (d, *J*_{C-P} = 26.4 Hz), 72.2 (d, *J*_{C-P} = 5.4 Hz), 24.2 (d, *J*_{C-P} = 3.8 Hz), 23.8 (d, *J*_{C-P} = 5.1 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 11.0 ppm. ESI HRMS *m*/*z* C₁₄H₂₁O₄P⁺ [M+H]⁺: calcd 285.1250; found 285.1255.

Dimethyl isobutyrylphosphonate. (4a) ¹H NMR (CDCl₃, 400 MHz): δ = 3.58 (d, *J* = 10.8 Hz, 6H), 2.86 (hept, *J* = 6.9 Hz, s1H), 0.90 (d, *J* = 7.1 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 213.4 (d, *J*_{C-P} = 156.8 Hz), 53.4 (d, *J*_{C-P} = 7.5 Hz), 41.1 (d, *J*_{C-P} = 54.9 Hz), 16.4 (d, *J*_{C-P} = 1.4 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = -1.1 ppm. ESI HRMS *m*/*z* C₆H₁₃O₄P⁺[M+H]⁺: calcd 181.0624; found 181.0626.

Diethyl isobutyrylphosphonate. (5a) ¹H NMR (CDCl₃, 400 MHz): $\delta = 3.98$ (p, J = 7.3 Hz, 4H), 2.93 (hept, J = 6.9 Hz, 1H), 1.13 (t, J = 7.2 Hz, 6H), 0.94 (d, J = 7.2 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 **MHz**): $\delta = 214.1$ (d, $J_{C-P} = 158.0$ Hz), 63.2 (d, $J_{C-P} = 7.4$ Hz), 41.0 (d, $J_{C-P} = 54.6$ Hz), 16.7 (d, $J_{C-P} = 1.4$ Hz), 16.0 (d, $J_{C-P} = 5.7$ Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = -3.0$ ppm. ESI HRMS m/z $C_8H_{17}O_4P^+$ [M+H]⁺: calcd 209.0937; found 209.0941.

Dimethyl (3-methylbutanoyl)phosphonate. (7a) ¹H NMR (CDCl₃, 400 MHz): δ = 3.62 (d, J = 10.8 Hz, 6H), 2.46 (d, J = 6.9 Hz, 2H), 2.01 (dp, J = 13.4, 6.7 Hz, 1H), 0.70 (d, J = 7.0 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 210.0 (d, J_{C-P} = 163.7 Hz), 53.5 (d, J_{C-P} = 7.4 Hz), 51.9 (d, J_{C-P} = 52.9 Hz), 23.2 (d, J_{C-P} = 3.7 Hz), 22.0 (d, J_{C-P} = 1.4 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = -1.4 ppm. ESI HRMS *m*/*z* C₇H₁₅O₄P⁺ [M+H]⁺: calcd 195.0780; found 195.0781.

Diethyl (3-methylbutanoyl)phosphonate. (8a) ¹H NMR (CDCl₃, 400 MHz): δ = 4.17 – 4.05 (m, 4H), 2.61 (d, *J* = 6.8 Hz, 2H), 2.23 – 2.10 (m, 1H), 1.27 (t, *J* = 7.1 Hz, 6H), 0.84 (d, *J* = 6.9 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 210.9 (d, *J*_{C-P} = 164.4 Hz), 63.6 (d, *J*_{C-P} = 7.3 Hz), 52.0 (d, *J*_{C-P} = 52.5 Hz), 23.5 (d, *J*_{C-P} = 3.7 Hz), 22.3 (d, *J*_{C-P} = 1.3 Hz), 16.3 (d, *J*_{C-P} = 5.5 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = -3.0 ppm. ESI HRMS *m*/*z* C₉H₁₉O₄P⁺ [M+H]⁺: calcd

223.1093; found 223.1097.



.OMe

✓ NOH C₁₀H₁₄NO₄P

MW 243,20

Diethyl (1-hydroxy-2-(4-methoxyphenyl)vinyl)phosphonate. (iso-13a) ¹H NMR (CDCl₃, 400 MHz): δ = 7.69 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.03 (d, J = 12.4 Hz, 1H), 4.22 - 4.07 (m, 4H), 3.77 (s, 3H), 1.34 (t, J = 7.1 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 159.0, 139.8 (d, J_{C-P} = 205.4 Hz), 131.1, 127.5 (d, J_{C-P} = 18.0 Hz), 116.4 (d, J_{C-P} = 27.5 Hz), 113.8, 63.0 (d, J_{C-P} = 5.3 Hz), 55.2, 16.3 (d, J_{C-P} = 6.5 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 13.6 ppm. ESI HRMS m/z C₁₃H₁₉O₅P⁺ [M+H]⁺: calcd 287.1042; found 287.1045.

Dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate. (1b) ¹H NMR (CDCl₃, 400 MHz): δ = 11.21 (s, br, 1H), 7.39 – 7.14 (m, 5H), 3.92 (d, *J* = 14.5 Hz, 0.92H, E_{iso}), 3.77 (d, *J* = 12.4 Hz, 1.11H, Z_{iso}), 3.63 (d, *J* = 11.5 Hz, 3.2H, Z_{iso}), 3.60 (d, *J* = 11.2 Hz, 3H, E_{iso}) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 151.7 (d, *J*_{C-P} = 215.1 Hz, E_{iso}), 150.2 (d, *J*_{C-P} = 153.9 Hz, Z_{iso}), 136.4 (d, *J*_{C-P} = 2.0 Hz, Z_{iso}), 135.6 (d, *J*_{C-P} = 1.5 Hz, E_{iso}), 129.4 (E_{iso}), 129.1 (Z_{iso}), 128.4 (Z_{iso}), 128.4 (E_{iso}), 126.7 (Z_{iso}), 126.6 (E_{iso}), 53.3 (d, *J*_{C-P} = 5.9 Hz, E_{iso}), 53.1 (d, *J*_{C-P} = 5.9 Hz, Z_{iso}), 38.6 (d, *J*_{C-P} = 18.7 Hz, Z_{iso}), 32.1 (d, *J*_{C-P} = 16.7 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 13.0 (E_{iso}), 8.3 (Z_{iso}) ppm. ESI HRMS *m*/*z* C₁₀H₁₄NO₄P⁺ [M+H]⁺: calcd 244.0733; found 244.0739.

OEt POEt NOH C₁₂H₁₈NO₄P MW 271,25



Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate. (2b) ¹H NMR (CDCl₃, 400 MHz): δ = 11.43 (s, br, 1H), 7.40 – 7.16 (m, 5H), 4.12 – 3.89 (m, 5.45H), 3.80 (d, *J* = 12.4 Hz, 0.55H, **Z**_{iso}), 1.24 – 1.14 (m, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 152.0 (d, *J*_{C-P} = 214.8 Hz, **E**_{iso}), 150.3 (d, *J*_{C-P} = 153.5 Hz, **Z**_{iso}), 136.6 (d, *J*_{C-P} = 1.8 Hz, **Z**_{iso}), 135.8 (d, *J*_{C-P} = 1.4 Hz, **E**_{iso}), 129.4 (**E**_{iso}), 129.1 (**Z**_{iso}), 128.3 (**Z**_{iso}), 128.2 (**E**_{iso}), 126.6 (**Z**_{iso}), 126.4 (**E**_{iso}), 63.0 (d, *J*_{C-P} = 5.9 Hz, **E**_{iso}), 62.7 (d, *J*_{C-P} = 5.9 Hz, **Z**_{iso}), 38.7 (d, *J*_{C-P} = 18.7 Hz, **Z**_{iso}), 32.0 (d, *J*_{C-P} = 16.6 Hz, **E**_{iso}), 16.1 (d, *J*_{C-P} = 6.5 Hz, **Z**_{iso}), 16.0 (d, *J*_{C-P} = 6.6 Hz, **E**_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.3 (**E**_{iso}), 5.4 (**Z**_{iso}) ppm. IR (neat): *v*_{max} = 3155, 3026, 2922, 2856, 1441, 1428, 1395, 1237, 1215, 1016, 974, 953 cm⁻¹. ESI HRMS *m*/*z* C₁₂H₁₈NO₄P⁺ [M+H]⁺: calcd 272.1046; found 272.1048.

Diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate. (3b) ¹H NMR (CDCl₃, 400 MHz): δ = 7.39 – 7.16 (m, 5H), 4.66 (dh, J = 12.2, 6.3 Hz, 2H), 3.92 (d, J = 14.0 Hz, 1.89H, \mathbf{E}_{iso}), 3.77 (d, J = 11.6 Hz, 0.12H, \mathbf{Z}_{iso}), 1.28 (d, J = 6.1 Hz, 6H), 1.15 (d, J = 6.2 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 153.8 (d, J_{C-P} = 215.4 Hz, \mathbf{E}_{iso}), 136.6 (\mathbf{Z}_{iso}), 136.0 (d, J_{C-P} = 1.6 Hz, \mathbf{E}_{iso}), 129.7 (\mathbf{E}_{iso}), 129.4 (\mathbf{Z}_{iso}), 128.4 (\mathbf{Z}_{iso}), 128.4 (\mathbf{E}_{iso}), 126.8 (\mathbf{Z}_{iso}), 126.6 (\mathbf{E}_{iso}), 72.2 (d, J_{C-P} = 6.2 Hz, \mathbf{Z}_{iso}), 72.0 (d, J_{C-P} = 6.2 Hz, \mathbf{E}_{iso}), 39.3 (d, J_{C-P} = 17.8 Hz, **Z**_{iso}), 32.2 (d, J_{C-P} = 15.8 Hz, **E**_{iso}), 24.1 (d, J_{C-P} = 3.8 Hz), 23.6 (d, J_{C-P} = 5.2 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 7.6 (**E**_{iso}), 3.2 (**Z**_{iso}) ppm. **ESI HRMS** m/z C₁₄H₂₂NO₄P⁺ [M+H]⁺: calcd 300.1359; found 300.1361.

Dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate. (4b) ¹H NMR (CDCl₃, 400 MHz): δ = 10.78 (s, br, 1H), 3.76 (dd, *J* = 12.3, 11.3 Hz, 6H), 3.40 – 3.23 (m, 0.45 H, E_{iso}), 2.89 – 2.71 (m, 0.54, **Z**_{iso}), 1.18 (d, *J* = 7.1 Hz, 3 H), 1.12 (d, *J* = 6.9 Hz, 3 H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 157.9 (d, *J*_{C-P} = 206.6 Hz, E_{iso}), 155.7 (d, *J*_{C-P} = 148.2 Hz, **Z**_{iso}), 53.3 (d, *J*_{C-P} = 6.3 Hz, E_{iso}), 53.0 (d, *J*_{C-P} = 6.0 Hz, **Z**_{iso}), 32.3 (d, *J*_{C-P} = 17.7 Hz, **Z**_{iso}), 27.1 (d, *J*_{C-P} = 16.3 Hz, E_{iso}), 20.7 (d, *J*_{C-P} = 3.6 Hz, **Z**_{iso}), 18.6 (d, *J*_{C-P} = 2.4 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 13.1 (E_{iso}), 9.1 (**Z**_{iso}) ppm. ESI HRMS *m*/*z* C₆H₁₄NO₄P⁺ [M+H]⁺: calcd 196.0733; found 196.0741.



NOH

C₆H₁₄NO₄P MW 195,15

> Diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate. (5b) ¹H NMR (CDCl₃, 400 MHz): $\delta = 10.95$ (s, br, 1H), 4.20 – 3.99 (m, 4H), 3.40 – 3.18 (m, 0.48 H, \mathbf{E}_{iso}), 2.87 – 2.70 (m, 0.43 H, \mathbf{Z}_{iso}), 1.25 (t, $J_{-}=7.1$ Hz, 6H), 1.15 (d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.9 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): $\delta = 158.1$ (d, $J_{C-P} = 206.8$ Hz, \mathbf{E}_{iso}), 155.7 (d, $J_{C-P} = 147.9$ Hz, \mathbf{Z}_{iso}), 62.8 (d, $J_{C-P} = 6.3$ Hz, \mathbf{E}_{iso}), 62.5 (d, $J_{C-P} = 5.9$ Hz, \mathbf{Z}_{iso}), 32.3 (d, $J_{C-P} = 17.9$ Hz, \mathbf{Z}_{iso}), 27.2 (d, $J_{C-P} = 16.4$ Hz, \mathbf{E}_{iso}), 20.7 (d, $J_{C-P} = 3.3$ Hz, \mathbf{Z}_{iso}), 18.6 (d, $J_{C-P} = 2.4$ Hz, \mathbf{E}_{iso}), 16.2 (t, $J_{C-P} = 6.0$ Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = 10.4$ (\mathbf{E}_{iso}), 6.1 (\mathbf{Z}_{iso}) ppm. ESI HRMS m/z C₈H₁₈NO₄P⁺[M+H]⁺: calcd 224.1046; found 224.1087.



Diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate. (6b) ¹H NMR (CDCl₃, 400 MHz): δ = 4.84 – 4.63 (m, 2H), 3.38 – 3.14 (m, 0.69H, E_{iso}), 2.89 – 2.70 (m, 0.28 H, Z_{iso}), 1.32 – 1.21 (m, 12H), 1.17 (d, *J* = 7.1 Hz, 4.16 H), 1.10 (d, *J* = 6.9 Hz, 1.74 H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 158.7 (d, *J*_{C-P} = 208.7 Hz, E_{iso}), 156.2 (d, *J*_{C-P} = 148.0 Hz, Z_{iso}), 71.6 (d, *J*_{C-P} = 6.4 Hz, E_{iso}), 71.5 (d, *J*_{C-P} = 6.3 Hz, Z_{iso}), 32.3 (d, *J*_{C-P} = 17.9 Hz, Z_{iso}), 27.4 (d, *J*_{C-P} = 16.2 Hz, E_{iso}), 24.2 (d, *J*_{C-P} = 3.5 Hz, Z_{iso}), 24.0 (d, *J*_{C-P} = 3.9 Hz, E_{iso}), 23.8 (d, *J*_{C-P} = 3.9 Hz, Z_{iso}), 20.9 (d, *J*_{C-P} = 3.4 Hz, Z_{iso}), 18.7 (d, *J*_{C-P} = 2.5 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 8.6 (E_{iso}), 3.7 (Z_{iso}) ppm. ESI HRMS *m*/*z* C₁₀H₂₂NO₄P⁺ [M+H]⁺: calcd 252.1359; found 252.1364.



Dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate. (7b) ¹**H NMR (CDCl₃, 400 MHz):** δ = 11.08 (s, br, 1H), 3.72 (t, *J* = 11.6 Hz, 6H), 2.35 (dd, *J* = 15.3, 7.5 Hz, 0.78 H, **E**_{iso}), 2.20 (dd, *J* = 12.9, 7.1 Hz, 1.19 H, **Z**_{iso}), 2.10 – 2.00 (m, 0.36 H, **E**_{iso}), 1.97 – 1.86 (m, 0.58 H, **Z**_{iso}), 0.83 (t, *J* = 7.1 Hz, 6H) ppm. ¹³**C NMR (CDCl₃, 100.6 MHz):** δ = 153.1 (d, *J*_{C-P} = 212.9 Hz, **E**_{iso}), 150.5 (d, *J*_{C-P} = 151.5 Hz, **Z**_{iso}), 53.4 (d, J_{C-P} = 6.3 Hz, **E**_{iso}), 53.0 (d, J_{C-P} = 6.0 Hz, **Z**_{iso}), 41.4 (d, J_{C-P} = 17.5 Hz, **Z**_{iso}), 35.0 (d, J_{C-P} = 16.0 Hz, **E**_{iso}), 26.5 (d, J_{C-P} = 1.8 Hz, **Z**_{iso}), 26.3 (d, J_{C-P} = 1.6 Hz, **E**_{iso}), 22.6, 22.2 ppm. ³¹P NMR (**CDCl₃, 161.9 MHz**): δ = 13.5 (**E**_{iso}), 9.1 (**Z**_{iso}) ppm. **ESI HRMS** *m/z* C₇H₁₆NO₄P⁺ [M+H]⁺: calcd 210.0889; found 210.0893.



Diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate. (8b) ¹H NMR (CDCl₃, 400 MHz): δ = 4.25 – 4.06 (m, 4H), 2.42 (dd, *J* = 15.0, 7.5 Hz, 1H), 2.26 (dd, *J* = 12.5, 7.1 Hz, 1H), 2.20 – 2.08 (m, 0.5 H), 2.07 – 1.92 (m, 0.5 H), 1.31 (t, *J* = 7.1 Hz, 6H), 0.91 (t, *J* = 6.9 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 154.5 (d, *J*_{C-P} = 211.3 Hz, E_{iso}), 151.7 (d, *J*_{C-P} = 150.7 Hz, Z_{iso}), 63.0 (d, *J*_{C-P} = 6.2 Hz), 62.7 (d, *J*_{C-P} = 6.1 Hz), 41.7 (d, *J*_{C-P} = 17.1 Hz), 35.2 (d, *J*_{C-P} = 15.4 Hz), 26.6 (d, *J*_{C-P} = 1.8 Hz), 26.4 (d, *J*_{C-P} = 1.5 Hz), 22.8, 22.4, 16.4 (t, *J*_{C-P} = 6.2 Hz, 2C) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.5 (E_{iso}), 5.9 (Z_{iso}) ppm. ESI HRMS *m*/*z* C₉H₂₀NO₄P⁺ [M+H]⁺: calcd 238.1202; found 238.1211.



Diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate. (9b) ¹H NMR (CDCl₃, 400 MHz): δ = 4.85 – 4.53 (m, 2H), 2.43 – 1.89 (m, 3H), 1.26 (dt, *J* = 11.8, 6.0 Hz, 12H), 0.89 – 0.81 (m, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 154.6 (d, *J*_{*C-P*} = 214.1 Hz, **E**_{iso}), 151.6 (d, *J*_{*C-P*} = 151.5 Hz, **Z**_{iso}), 71.6 (d, *J*_{*C-P*} = 6.3 Hz, **E**_{iso}), 71.5 (d, *J*_{*C-P*} = 6.3 Hz, **Z**_{iso}), 41.8 (d, *J*_{*C-P*} = 17.5 Hz, **Z**_{iso}), 35.1 (d, *J*_{*C-P*} = 15.8 Hz, **E**_{iso}), 26.5 (d, *J*_{*C-P*} = 1.8 Hz, **Z**_{iso}), 26.3 (d, *J*_{*C-P*} = 1.5 Hz, **E**_{iso}), 24.2 (d, *J*_{*C-P*} = 3.3 Hz, **Z**_{iso}), 24.0 (d, *J*_{*C-P*} = 3.9 Hz, **E**_{iso}), 23.8 (d, *J*_{*C-P*} = 5.3 Hz, **Z**_{iso}), 23.7 (d, *J*_{*C-P*} = 5.1 Hz, **E**_{iso}), 22.8, 22.3 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 8.7 (**E**_{iso}), 3.5 (**Z**_{iso}) ppm. ESI HRMS *m*/*z* C₁₁H₂₄NO₄P⁺[M+H]⁺: calcd 266.1515; found 266.1516.





Diethyl (1-(hydroxyimino)ethyl)phosphonate. (10b) ¹H NMR (CDCl₃, 400 MHz): δ = 11.09 (s, br, 1H), 4.15 – 3.99 (m, 4H), 1.95 (d, *J* = 11.2 Hz, 3H), 1.26 (t, *J* = 7.1 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 150.3 (d, *J*_{C-P} = 217.8 Hz, E_{iso}), 62.9 (d, *J*_{C-P} = 5.9 Hz), 16.2 (d, *J*_{C-P} = 6.4 Hz), 11.7 (d, *J*_{C-P} = 16.6 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.7 (E_{iso}), 5.3 (Z_{iso}) ppm. ESI HRMS *m/z* C₆H₁₄NO₄P⁺ [M+H]⁺: calcd 196.0733; found 196.0788.

Diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate. (11b) ¹H NMR (CDCl₃, 400 MHz): $\delta = 4.24 - 4.03$ (m, 4H), 1.37 - 1.20 (m, 15H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): $\delta = 158.4$ (d, $J_{C-P} = 202.1$ Hz, E_{iso}), 157.6 (d, $J_{C-P} = 141.3$ Hz, Z_{iso}), 62.8 (d, $J_{C-P} = 6.4$ Hz, E_{iso}), 62.4 (d, $J_{C-P} = 6.1$ Hz, Z_{iso}), 38.3 (d, $J_{C-P} = 18.7$ Hz, Z_{iso}), 37.0 (d, $J_{C-P} = 17.3$ Hz, E_{iso}), 28.5 (d, $J_{C-P} = 2.8$ Hz, Z_{iso}), 27.6 (d, $J_{C-P} = 3.8$ Hz, E_{iso}), 16.3 (t, $J_{C-P} = 7.0$ Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = 11.4$ (E_{iso}), 6.7 (Z_{iso}) ppm. IR (neat): $v_{max} = 3152$, 2979, 2911, 1436, 1237, 1215, 1016, 974, 954 cm⁻¹. ESI HRMS m/z C₉H₂₀NO₄P⁺ [M+H]⁺: calcd 238.1202; found 238.1208.



Diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate. (12b) ¹H NMR (CDCl₃, 400 MHz): δ = 10.74 (s, br, 1H), 4.26 – 3.98 (m, 4H), 3.19 – 3.00 (m, 0.30H, E_{iso}), 2.71 – 2.52 (m, 0.67H, Z_{iso}), 1.84 – 1.33 (m, 2H), 1.29 (t, *J* = 7.1 Hz, 6H), 1.16 (d, *J* = 7.1 Hz, 0.90H, E_{iso}), 1.10 (d, *J* = 6.9 Hz, 2.05H, Z_{iso}), 0.85 (t, *J* = 7.4 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 157.9 (d, *J*_{C-P} = 206.1 Hz, E_{iso}), 155.5 (d, *J*_{C-P} = 147.4 Hz, Z_{iso}), 62.8 (d, *J*_{C-P} = 6.3 Hz, E_{iso}), 62.6 (dd, *J*_{C-P} = 7.5, 6.1 Hz, Z_{iso}), 39.0 (d, *J*_{C-P} = 17.0 Hz, Z_{iso}), 34.6 (d, *J*_{C-P} = 16.0 Hz, E_{iso}), 27.7 (d, *J*_{C-P} = 2.9 Hz, Z_{iso}), 26.3 (d, *J*_{C-P} = 2.5 Hz, E_{iso}), 18.2 (d, *J*_{C-P} = 3.3 Hz), 16.3 (t, *J*_{C-P} = 6.1 Hz), 12.4 (E_{iso}), 11.8 (Z_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.5 (E_{iso}), 6.2 (Z_{iso}) ppm. IR (neat): *v*_{max} = 3162, 2968, 2875, 1444, 1392, 1221, 1017, 973, 946 cm⁻¹. ESI HRMS *m*/*z* C₉H₂₀NO₄P⁺ [M+H]⁺: calcd 238.1202; found 238.1205.

Diethyl

(1-(hydroxyimino)-2-(4-



methoxyphenyl)ethyl)phosphonate. (13b) ¹H NMR (CDCl₃, 400 MHz): δ = 11.49 (s, br, 1H), 7.39 – 7.21 (m, 2H), 6.86 (t, *J* = 7.9 Hz, 2H), 4.25 – 3.96 (m, 4H), 3.93 (d, *J* = 14.5 Hz, 1.47H, E_{iso}), 3.87 – 3.72 (m, 3.50H), 1.32 – 1.19 (m, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 158.3 (Z_{iso}), 158.1 (E_{iso}), 152.3 (d, *J*_{C-P} = 213.9 Hz, E_{iso}), 150.4 (d, *J*_{C-P} = 152.7 Hz, Z_{iso}), 130.4 (E_{iso}), 130.1 (Z_{iso}), 128.5 (Z_{iso}), 127.8 (E_{iso}), 113.6 (Z_{iso}), 113.6 (E_{iso}), 62.9 (d, *J*_{C-P} = 5.9 Hz, E_{iso}), 62.5 (d, *J*_{C-P} = 5.8 Hz, Z_{iso}), 55.1, 37.8 (d, *J*_{C-P} = 18.8 Hz, Z_{iso}), 31.0 (d, *J*_{C-P} = 16.8 Hz, E_{iso}), 16.0 (d, *J*_{C-P} = 6.6 Hz, Z_{iso}), 15.9 (d, *J*_{C-P} = 6.5 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.4 (E_{iso}), 5.5 (Z_{iso}) ppm. IR (neat): *v*_{max} = 3155, 2988, 1611, 1511, 1442, 1244, 1211, 1177, 1016, 974, 953 cm⁻¹. ESI HRMS *m*/z C₁₃H₂₀NO₅P⁺ [M+H]⁺: calcd 302.1151; found 302.1154.



Diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate. (14b) ¹H NMR (CDCl₃, 400 MHz): δ = 10.91 (s, br, 1H, E_{iso}), 4.23 – 4.04 (m, 4H), 2.82 – 2.71 (m, 2H), 2.70 – 2.62 (m, 2H), 2.10 (s, 2.76H, E_{iso}), 2.07 (s, 0.23H, Z_{iso}), 1.29 (t, *J* = 7.1 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 152.3 (d, *J*_{C-P} = 214.9 Hz, E_{iso}), 150.1 (d, *J*_{C-P} = 153.0 Hz, Z_{iso}), 63.2 (d, *J*_{C-P} = 6.2 Hz, E_{iso}), 62.9 (d, *J*_{C-P} = 6.0 Hz, Z_{iso}), 33.0 (d, *J*_{C-P} = 17.8 Hz, Z_{iso}), 31.4 (d, *J*_{C-P} = 3.0 Hz, Z_{iso}), 29.6 (d, *J*_{C-P} = 2.1 Hz, E_{iso}), 26.6 (d, *J*_{C-P} = 15.8 Hz, E_{iso}), 16.3 (d, *J*_{C-P} = 6.4 Hz), 16.2 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.1 (E_{iso}), 5.1 (Z_{iso}) ppm. ESI HRMS *m*/*z* C₈H₁₈NO₄PS⁺ [M+H]⁺: calcd 256.0766; found 256.0803.



Diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate. (15b) ¹H NMR (CDCl₃, 400 MHz): δ = 11.28 (s, br, 0.66H, E_{iso}), 10.97 (s, br, 0.28H, Z_{iso}), 7.48 – 7.13 (m, 5H), 4.28 – 4.02 (m, 4H), 3.97 (d, *J* = 13.6 Hz, 1.36H, E_{iso}), 3.84 (d, *J* = 12.0 Hz, 0.62H, Z_{iso}), 1.35 – 1.22 (m, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 150.0 (d, *J*_{C-P} = 219.3 Hz, E_{iso}), 147.7 (d, *J*_{C-P} = 159.2 Hz, Z_{iso}), 135.9 (E_{iso}), 134.9 (Z_{iso}), 131.2, 130.1, 128.9, 127.0, 126.6, 63.4 (d, *J*_{C-P} = 5.9 Hz, E_{iso}), 63.2 (d, *J*_{C-P} = 6.1 Hz, Z_{iso}), 36.7 (d, *J*_{C-P} = 20.2 Hz, Z_{iso}), 27.9 (d, *J*_{C-P} = 18.2 Hz, E_{iso}), 16.3 (d, *J*_{C-P} = 6.6 Hz, Z_{iso}), 16.2 (d, *J*_{C-P} = 6.6 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 9.1 (E_{iso}), 4.2 (Z_{iso}) ppm. ESI HRMS *m*/*z* C₁₂H₁₈NO₄PS⁺ [M+H]⁺: calcd 304.0766; found 304.0783.



Diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate. (16b) ¹H NMR (CDCl₃, 400 MHz): δ = 10.35 (s, br, 1H), 8.61 (s, 0.52H, \mathbf{Z}_{iso}), 8.49 (s, 0.46H, \mathbf{E}_{iso}), 7.68 (d, J = 8.0 Hz, 0.46H, \mathbf{E}_{iso}), 7.59 (d, J = 8 Hz, 0.55H, **Z**_{iso}), 7.30 (d, J = 0.9 Hz, 0.44H, **E**_{iso}), 7.28 (d, J = 1.0 Hz, 0.55H, **Z**_{iso}), 7.18 - 6.99 (m, 3H), 4.10 - 3.77 (m, 6H), 1.12 (td, J = 7.1, 0.5 Hz, 3.24H, **Z**_{iso}), 1.07 (td, J = 7.0, 0.6 Hz, 2.71H, **E**_{iso}) ppm. ¹³**C NMR (CDCl₃, 100.6 MHz):** δ = 153.7 (d, J_{C-P} = 212.1 Hz, \mathbf{E}_{iso}), 150.9 (d, J_{C-P} = 152.0 Hz, \mathbf{Z}_{iso}), 136.4 (\mathbf{Z}_{iso}), 136.1 (\mathbf{E}_{iso}), 127.5 (**E**_{iso}), 127.3 (**Z**_{iso}), 124.4 (**E**_{iso}), 124.1 (**Z**_{iso}), 121.9 (**Z**_{iso}), 121.8 (E_{iso}), 119.3 (Z_{iso}), 119.3 (E_{iso}), 119.0 (E_{iso}), 118.8 (Z_{iso}), 111.4 (Z_{iso}), 111.3 (\mathbf{E}_{iso}), 110.2 (d, J_{C-P} = 2.2 Hz, \mathbf{Z}_{iso}), 108.7 (d, J_{C-P} = 1.6 Hz, \mathbf{E}_{iso}), 63.1 (d, J_{C-P} = 5.8 Hz, **E**_{iso}), 63.0 (d, J_{C-P} = 5.9 Hz, **Z**_{iso}), 29.0 (d, J_{C-P} = 18.3 Hz, Z_{iso}), 22.0 (d, J_{C-P} = 16.0 Hz, E_{iso}), 16.2 (d, J_{C-P} = 6.4 Hz, Z_{iso}), 16.1 (d, J_{C-P} = 6.6 Hz, E_{iso}) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 10.0 (**E**_{iso}), 5.8 (**Z**_{iso}) ppm. **ESI HRMS** *m*/*z* C₁₄H₁₉N₂O₄P⁺ [M+H]⁺: calcd 311.1155; found 311.1159.



Dimethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate. (1c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.39 – 7.22 (m, 5H), 3.82 (d, J = 10.7 Hz, 3H), 3.75 (d, J = 10.7 Hz, 3H), 3.48 (dt, J = 14.3, 7.1 Hz, 1H), 3.13 (t, J = 9.2 Hz, 2H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 137.4 (d, J_{C-P} = 12.8 Hz), 129.3, 128.6, 126.8, 60.7 (d, J_{C-P} = 152.7 Hz), 53.0 (d, J_{C-P} = 6.3 Hz), 52.6 (d, J_{C-P} = 6.8 Hz), 32.6 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 28.9 ppm. ESI HRMS *m/z* C₁₀H₁₆NO₄P⁺[M+H]⁺: calcd 246.0889; found 246.0891.



Diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate. (2c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.40 – 7.22 (m, 5H), 6.26 (s, br, 1H), 4.27 – 4.06 (m, 4H), 3.45 (ddd, *J* = 13.9, 8.9, 5.5 Hz, 1H), 3.19 – 3.02 (m, 2H), 1.37 (t, *J* = 7.1 Hz, 3H), 1.30 (t, *J* = 7.1 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 137.6 (d, *J*_{C-P} = 12.5 Hz), 129.4, 128.7, 126.9, 62.5 (d, *J*_{C-P} = 6.6 Hz), 62.2 (d, *J*_{C-P} = 6.9 Hz), 61.3 (d, *J*_{C-P} = 153.6 Hz), 32.8, 16.6 (d, *J*_{C-P} = 6.0 Hz), 16.5 (d, *J*_{C-P} = 7.0 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 26.0 ppm. ESI HRMS *m/z*

$C_{12}H_{20}NO_4P^+[M+H]^+$: calcd 274.1202; found 274.1204.



Diisopropyl (1-(hydroxyamino)-2-phenylethyl)phosphonate. (3c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.41 – 7.23 (m, 5H), 4.90 – 4.71 (m, 2H), 3.39 (ddd, *J* = 12.8, 9.7, 4.6 Hz, 1H), 3.06 (m, 2H), 1.42 – 1.24 (m, 12H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 137.7 (d, *J*_{*C-P*} = 12.9 Hz), 129.5, 128.7, 126.9, 71.3 (d, *J*_{*C-P*} = 6.9 Hz), 71.0 (d, *J*_{*C-P*} = 7.0 Hz), 62.0 (d, *J*_{*C-P*} = 156.2 Hz), 33.0, 24.4 (d, *J*_{*C-P*} = 3.2 Hz), 24.2 (d, *J*_{*C-P*} = 3.6 Hz), 24.1 – 24.0 (m, 2C) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 23.9 ppm. ESI HRMS *m*/*z* C₁₄H₂₄NO₄P⁺ [M+H]⁺: calcd 302.1515; found 302.1517.



Dimethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate. (4c) ¹H NMR (CDCl₃, 400 MHz): δ = 3.79 (d, *J* = 5.1 Hz, 3H), 3.76 (d, *J* = 5.1 Hz, 3H), 3.02 (dd, *J* = 14.3, 6.2 HZ, 1H), 2.23 (dq, *J* = 13.3, 6.6 Hz, 1H), 1.08 (dd, *J* = 10.9, 6.9 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 65.6 (d, *J*_{C-P} = 142.2 Hz), 52.8 (d, *J*_{C-P} = 6.7 Hz), 52.6 (d, *J*_{C-P} = 7.0 Hz), 27.3, 20.8 (d, *J*_{C-P} = 7.5 Hz), 19.3 (d, *J*_{C-P} = 7.2 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 30.2 ppm. ESI HRMS *m/z* C₆H₁₆NO₄P⁺ [M+H]⁺: calcd 198.0889; found 198.0891.



Diethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate. (5c) ¹H NMR (CDCl₃, 400 MHz): $\delta = 7.04$ (s, br, 1H), 5.52 (s, br, 1H), 4.09 - 3.95 (m, 4H), 2.87 (dd, J = 15.0, 5.9 Hz, 1H), 2.15 (dq, J = 13.7, 6.8 Hz, 1H), 1.19 (td, J = 7.1, 2.2 Hz, 6H), 0.96 (dd, J = 10.0, 6.9 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): $\delta = 65.5$ (d, $J_{C-P} = 141.5$ Hz), 61.7 (d, $J_{C-P} = 6.7$ Hz), 61.6 (d, $J_{C-P} = 7.0$ Hz), 27.0 (d, $J_{C-P} = 1.5$ Hz), 20.5 (d, $J_{C-P} = 7.6$ Hz), 19.1 (d, $J_{C-P} = 6.7$ Hz), 16.3 (d, $J_{C-P} = 1.6$ Hz), 16.2 (d, $J_{C-P} = 1.6$ Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = 27.6$ ppm. ESI HRMS m/z C₈H₂₀NO₄P⁺ [M+H]⁺: calcd 226.1202; found 226.1204.



Diisopropyl (1-(hydroxyamino)-2-methylpropyl)phosphonate. (6c) ¹H NMR (CDCl₃, 400 MHz): $\delta = 4.75 - 4.60$ (m, 2H), 2.83 (dd, J = 14.8, 6.0 Hz, 1H), 2.15 (dq, J = 13.4, 6.7 Hz, 1H), 1.23 (dd, J =6.7, 5.3 Hz, 12H), 0.99 (dd, J = 9.2, 6.9 Hz, 6H) ppm. ¹³C (CDCl₃, 100.6 MHz): $\delta = 70.5$ (d, $J_{C-P} = 7.1$ Hz), 70.4 (d, $J_{C-P} = 7.4$ Hz), 66.3 (d, $J_{C-P} = 142.7$ Hz), 27.2, 24.1 (d, $J_{C-P} = 3.6$ Hz), 24.1 (d, $J_{C-P} = 3.8$ Hz), 23.9 (d, $J_{C-P} = 5.0$ Hz), 23.8 (d, $J_{C-P} = 5.2$ Hz), 20.7 (d, $J_{C-P} = 7.4$ Hz), 19.3 (d, $J_{C-P} = 7.0$) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = 25.6$ ppm. ESI HRMS m/z C₁₀H₂₄NO₄P⁺ [M+H]⁺: calcd 254.1515; found 254.1517.



Dimethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate. (7c) ¹H NMR (CDCl₃, 400 MHz): δ = 3.46 (dd, *J* = 11.0, 4.4 Hz, 6H), 2.94 (ddd, *J* = 13.9, 9.7, 4.6 Hz, 1H), 1.59 (hept, *J* = 6.7 Hz, 1H), 1.51 – 1.36 (m, 1H), 1.22 – 1.09 (m, 1H), 0.62 (dd, *J* = 16.8, 6.8 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 56.9 (d, *J*_{C-P} = 143.7 Hz), 52.1 (d, *J*_{C-P} = 6.3 Hz), 51.8 (d, *J*_{C-P} = 7.2 Hz), 35.3, 24.1 (d, *J*_{C-P} = 11.0 Hz), 22.6, 21.1 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 31.5 ppm. ESI HRMS *m*/*z* C₇H₁₈NO₄P⁺ [M+H]⁺: calcd 212.1046; found 212.1047.



Diethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate. (8c) ¹H NMR (CDCl₃, 400 MHz): δ = 4.14 – 3.97 (m, 4H), 3.16 (ddd, J = 13.6, 9.2, 4.8 Hz, 1H), 1.85 – 1.72 (m, 1H), 1.68 – 1.57 (m, 1H), 1.48 – 1.36 (m, 1H), 1.24 (t, J = 7.1 Hz, 6H), 0.85 (dd, J = 14.2, 6.6 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 62.1 (d, J_{C-P} = 6.5 Hz), 61.9 (d, J_{C-P} = 7.0 Hz), 57.7 (d, J_{C-P} = 146.7 Hz), 35.9, 24.8 (d, J_{C-P} = 10.6 Hz), 23.0, 21.7, 16.4 (dd, J_{C-P} = 5.9, 1.0 Hz, 2C) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 28.2 ppm. ESI HRMS *m/z* C₉H₂₂NO₄P⁺ [M+H]⁺: calcd 240.1359; found 240.1361.

Diisopropyl (1-(hydroxyamino)-3-methylbutyl)phosphonate. (9c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.21 (s, br, 1H), 5.37 (s, br, 1H), 4.67 – 4.51 (m, 2H), 3.00 (ddd, J = 13.6, 8.8, 4.9 Hz, 1H), 1.80 – 1.69 (m, 1H), 1.59 – 1.47 (m, 1H), 1.39 – 1.28 (m, 1H), 1.22 – 1.12 (m, 12H), 0.76 (dd, J = 13.7, 6.5 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 70.4 (d, J_{C-P} = 6.7 Hz), 70.2 (d, J_{C-P} = 7.2 Hz), 58.1 (d, J_{C-P} = 147.1 Hz), 36.1, 24.6 (d, J_{C-P} = 10.1 Hz), 24.0 (d, J_{C-P} = 2.8 Hz), 23.9 (d, J_{C-P} = 3.6 Hz), 23.8 (d, J_{C-P} = 4.9 Hz), 23.7 (d, J_{C-P} = 5.5 Hz), 22.9, 21.7 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 26.1 ppm. ESI HRMS m/z C₁₁H₂₆NO₄P⁺ [M+H]⁺: calcd 268.1672; found 268.1673.

Diethyl (1-(hydroxyamino)ethyl)phosphonate. (10c) ¹H NMR (D₂O, 400 MHz): δ = 4.22 – 4.10 (m, 4H), 3.96 (dq, *J* = 14.6, 7.2 Hz, 1H), 1.43 (dd, *J* = 16.6, 7.3 Hz, 3H), 1.24 (td, *J* = 7.1, 1.6 Hz, 6H) ppm. ¹³C NMR (D₂O, 100.6 MHz): δ = 65.2 (d, *J*_{C-P} = 2.2 Hz), 65.1 (d, *J*_{C-P} = 2.0 Hz), 52.7 (d, *J*_{C-P} = 155.6 Hz), 15.6 (d, *J*_{C-P} = 3.6 Hz), 15.6 (d, *J*_{C-P} = 3.6 Hz), 9.3 (d, *J*_{C-P} = 3.1 Hz) ppm. ³¹P NMR (D₂O, 161.9 MHz): δ = 19.0 ppm. ESI HRMS *m*/*z* C₆H₁₆NO₄P⁺ [M+H]⁺: calcd 198.0889; found 198.0891.



.OEt

NHOH

C₆H₁₆NO₄P

MW 197,17

Diethyl (1-(hydroxyamino)-2,2-dimethylpropyl)phosphonate. (11c) ¹H NMR (CDCl₃, 400 MHz): δ = 4.13 – 4.01 (m, 4H), 2.85 (d, J = 15.6 Hz, 1H), 1.23 (td, J = 7.1, 3.7 Hz, 6H), 1.01 (s, 9H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 69.5 (d, J_{C-P} = 139.4 Hz), 61.9 (d, J_{C-P} = 4.3 Hz), 61.8 (d, J_{C-P} = 4.3 Hz), 34.0 (d, J_{C-P} = 3.4 Hz), 28.1 (d, J_{C-P} = 6.2 Hz, 3C), 16.4 (d, J_{C-P} = 2.0 Hz), 16.3 (d, J_{C-P} = 2.1 Hz) ppm. ³¹P



NMR (**CDCl**₃, **161.9 MHz**): δ = 27.5 ppm. **ESI HRMS** *m/z* C₉H₂₂NO₄P⁺ [M+H]⁺: calcd 240.1359; found 240.1361.



Diethyl (1-(hydroxyamino)-2-methylbutyl)phosphonate (exist as a pair of diastereoisomers). (12c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.13 (s, br, 1H), 5.44 (s, br, 1H), 4.08 – 3.94 (m, 4H), 3.07 (dd, J = 15.5, 4.3 Hz, 0.5H), 2.98 (dd, J = 15.4, 5.7 Hz, 0.5H), 2.01 – 1.81 (m, 1H), 1.66 – 1. 40 (m, 1H), 1.32 – 1.11 (m, 7H), 0.92 (dd, J = 10.8, 7.0 Hz, 3H), 0.84 – 0.70 (m, 3H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 63.9 (d, J_{C-P} = 141.8 Hz), 62.8 (d, J_{C-P} = 141.8 Hz), 61.7 (m, 2C), 33.9, 33.3, 27.4 (d, J_{C-P} = 10.6 Hz), 25.5 (d, J_{C-P} = 5.6 Hz), 16.2 (m, 2C), 15.2, 15.2, 11.8, 11.3 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 27.7, 27.6 ppm (diastereoisomers). ESI HRMS m/zC₉H₂₂NO₄P⁺ [M+H]⁺: calcd 240.1359; found 240.1361.



Diethyl (1-(hydroxyamino)-2-(4methoxyphenyl)ethyl)phosphonate. (13c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.17 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.21 – 4.02 (m, 4H), 3.77 (s, 3H), 3.35 (ddd, J = 13.8, 9.2, 5.1 Hz, 1H), 3.08 – 2.92 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 158.6, 130.4, 129.4 (d, J_{C-P} = 12.9 Hz), 114.1, 62.5 (d, J_{C-P} = 6.6 Hz), 62.2, 61.5 (d, J_{C-P} = 152.9 Hz), 55.4, 31.9, 16.5 (t, J_{C-P} = 6.1 Hz, 2C) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 26.1 ppm. ESI HRMS *m*/*z* C₁₃H₂₂NO₅P⁺ [M+H]⁺: calcd 304.1308; found 304.1311.





Diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate. (14c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.18 (s, br, 1H), 5.58 (s, br, 1H), 4.00 – 3.88 (m, 4H), 3.24 – 3.12 (m, 1H), 2.60 – 2.41 (m, 2H), 1.98 – 1.70 (m, 5H), 1.12 (td, *J* = 7.0, 2.4 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 61.8 (d, *J*_{C-P} = 6.4 Hz), 61.6 (d, *J*_{C-P} = 6.8 Hz), 57.6 (d, *J*_{C-P} = 144.3 Hz), 30.5 (d, *J*_{C-P} = 11.8 Hz), 25.8, 16.1 (d, *J*_{C-P} = 2.3 Hz), 16.0 (d, *J*_{C-P} = 2.5 Hz), 14.6 ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 27.5 ppm. ESI HRMS *m*/*z* C₈H₂₀NO₄PS⁺ [M+H]⁺: calcd 258.0923; found 258.0924.

Diethyl (1-(hydroxyamino)-2-(phenylthio)ethyl)phosphonate. (15c) ¹H NMR (CDCl₃, 400 MHz): δ = 7.42 – 7.15 (m, 5H), 6.65 (s, br, 1H), 5.87 (s, br, 1H), 4.23 – 4.04 (m, 4H), 3.42 – 3.19 (m, 3H), 1.29 (dt, *J* = 11.1, 7.1 Hz, 6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): δ = 135.0, 130.0, 129.2, 126.7, 62.7 (d, *J*_{C-P} = 6.5 Hz), 62.4 (d, *J*_{C-P} = 6.9 Hz), 58.6 (d, *J*_{C-P} = 151.5 Hz), 31.4 (d, *J*_{C-P} = 4.8 Hz), 16.5 (d, *J*_{C-P} = 3.9 Hz), 16.4 (d, *J*_{C-P} = 4.0 Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): δ = 24.5 ppm. ESI HRMS *m*/*z* C₁₂H₂₀NO₄PS⁺ [M+H]⁺: calcd 306.0923; found 306.0925.

Diethyl (1-(hydroxyamino)-2-(1*H***-indol-3-yl)ethyl)phosphonate.** (16c) ¹H NMR (CDCl₃, 400 MHz): δ = 8.46 (s, 1H), 7.61 – 7.55 (m,



6H) ppm. ¹³C NMR (CDCl₃, 100.6 MHz): $\delta = 137.6$ (d, $J_{C-P} = 15.7$ Hz), 128.9, 128.2, 126.4, 62.0, 50.0 (d, $J_{C-P} = 154.1$ Hz), 37.5, 16.2 (d, $J_{C-P} = 5.5$ Hz) ppm. ³¹P NMR (CDCl₃, 161.9 MHz): $\delta = 27.9$ ppm. IR (neat): $v_{max} = 2981$, 1603, 1495, 1454, 1391, 1231, 1163, 1050, 1020, 956 cm⁻¹. ESI HRMS m/z C₁₂H₂₀NO₃P⁺ [M+H]⁺: calcd 258.1253; found 258.1251.

2.3 LC analysis

2.3.1 Analytical Method

Eluent:A: Water + 0.1% Formic acid (v/v)B: Acetonitrile

Gradient Table:

Time	А	В		
[min]	[%]	[%]		
0	100	0		
20	20	80		
23	20	80		
23.01	100	0		
26	100	0		
Flow :	1 mL min ⁻¹			
Injection Volume :	5-10 μL	5-10 μL		
Column :	C18, 100 × 4	C18, 100 $ imes$ 4.6 mm, 3 μ m		
Oven Temperature :	40 °C	40 °C		
Diode Array Detector	r: 180-800 nm	180-800 nm		



$\begin{array}{cc} \text{2.3.2} & \text{Copies of representative LC traces} \\ & {}_{\text{mAU}} \end{array}$

Peak Table

PDA Ch1 220nm					
Peak#	Ret. Time	Area	Height	Area%	
1	12,128	4350887	831958	30,091	
2	12,794	10108313	1862825	69,909	
Total		14459201	2694782	100,000	

Figure S1. LC trace of the reduction of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**2b**). Crude reaction mixture at t = 0 min. Peak identification was conducted using purified substances by micropreparative HPLC and analyzed by HRMS as well as comparison with the ³¹P NMR ratios. Peak #1 (12.128 min) = compound **2b** (Z_{iso}), peak #2 (12.794 min) = compound **2b** (E_{iso}).



Figure S2. LC trace of the reduction of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**2b**). Crude reaction mixture at t = 60 min highlighting the total reduction of the Z_{iso} while the E_{iso} remains untouched. Peak identification was conducted using purified substances by micropreparative HPLC and analyzed by HRMS. Peak #1 (12.799 min) = compound **2b** (E_{iso}).



Figure S3. LC trace of the reduction of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**2b**). Crude reaction mixture at t = 1 day highlighting the total reduction of the Z_{iso} while the E_{iso} remains untouched. Peak identification was conducted using purified substances by micropreparative HPLC and analyzed by HRMS. Peak #1 (12.760 min) = compound **2b** (E_{iso}).



Figure S4. LC trace of the reduction of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**2b**). Crude reaction mixture at t = 1 week highlighting the total reduction of the Z_{iso} while the E_{iso} remains untouched. Peak identification was conducted using purified substances by micropreparative HPLC and analyzed by HRMS. Peak #1 (12.862 min) = compound **2b** (E_{iso}).

2.4 Copies of ¹H, ¹³C and ³¹P NMR spectra



Figure S5. ¹H NMR spectrum (400 MHz) of 2-(phenylthio)acetyl chloride (ac-15) in CDCl₃.



Figure S6. ¹³C APT NMR spectrum (100.6 MHz) of 2-(phenylthio)acetyl chloride (ac-15) in CDCl₃.







Figure S8. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate (**iso-3a**) in CDCl₃.



Figure S9. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-hydroxy-2-phenylvinyl)phosphonate (**iso-3a**) in CDCl₃.







Figure S11. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl isobutyrylphosphonate (4a) in CDCl₃.



Figure S12. ³¹P NMR spectrum (161.9 MHz) of dimethyl isobutyrylphosphonate (4a) in CDCl₃.



Figure S13. ¹H NMR spectrum (400 MHz) of diethyl isobutyrylphosphonate (5a) in CDCl₃.



Figure S14. ¹³C APT NMR spectrum (100.6 MHz) of diethyl isobutyrylphosphonate (5a) in CDCl₃.



Figure S15. ³¹P NMR spectrum (161.9 MHz) of diethyl isobutyrylphosphonate (5a) in CDCl₃.



Figure S16. ¹H NMR spectrum (400 MHz) of dimethyl (3-methylbutanoyl)phosphonate (7a) in CDCl₃.


Figure S17. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (3-methylbutanoyl)phosphonate (**7a**) in CDCl₃.



Figure S18. ³¹P NMR spectrum (161.9 MHz) of dimethyl (3-methylbutanoyl)phosphonate (7a) in $CDCI_3$.



Figure S19. ¹H NMR spectrum (400 MHz) of diethyl (3-methylbutanoyl)phosphonate (8a) in CDCl₃.



Figure S20. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (3-methylbutanoyl)phosphonate (8a) in CDCl₃.



Figure S21. ³¹P NMR spectrum (161.9 MHz) of diethyl (3-methylbutanoyl)phosphonate (8a) in CDCl₃.



Figure S22. ¹H NMR spectrum (400 MHz) of diethyl (1-hydroxy-2-(4-methoxyphenyl)vinyl)phosphonate (**iso-13a**) in CDCl₃.



Figure S23. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-hydroxy-2-(4-methoxyphenyl)vinyl)phosphonate (**iso-13a**) in CDCl₃.



Figure S24. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-hydroxy-2-(4-methoxyphenyl)vinyl)phosphonate (**iso-13a**) in CDCl₃.



Figure S25. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**1b**) in CDCl₃.



Figure S26. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**1b**) in $CDCl_3$.



Figure S27. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**1b**) in $CDCI_3$.



Figure S28. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b) in CDCl₃.



Figure S29. 13 C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b) in CDCl₃.



Figure S30. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**2b**) in $CDCl_3$.



Figure S31. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**3b**) in $CDCl_3$.



Figure S32. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**3b**) in $CDCI_3$.



Figure S33. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**3b**) in $CDCI_3$.



Figure S34. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**4b**) in $CDCl_3$.



Figure S35. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**4b**) in $CDCl_3$.



Figure S36. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**4b**) in $CDCl_3$.



Figure S37. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**5b**) in CDCl₃.



Figure S38. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**5b**) in CDCl₃.



Figure S39. 31 P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**5b**) in CDCl₃.



Figure S40. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**6b**) in $CDCl_3$.



Figure S41. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**6b**) in $CDCl_3$.



Figure S42. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**6b**) in $CDCl_3$.



Figure S43. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**7b**) in CDCl₃.



Figure S44. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**7b**) in $CDCl_3$.



Figure S45. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**7b**) in $CDCl_3$.



Figure S46. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**8b**) in CDCl₃.



Figure S47. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**8b**) in $CDCl_3$.



Figure S48. 31 P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**8b**) in CDCl₃.



Figure S49. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**9b**) in $CDCl_3$.



Figure S50. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**9b**) in $CDCl_3$.



Figure S51. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**9b**) in $CDCl_3$.



Figure S52. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)ethyl)phosphonate (10b) in $CDCI_3$.



Figure S53. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)ethyl)phosphonate (**10b**) in CDCl₃.



Figure S54. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)ethyl)phosphonate (**10b**) in CDCl₃.



Figure S55. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**) in $CDCl_3$.



Figure S56. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**) in $CDCl_3$.



Figure S57. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**) in $CDCl_3$.



Figure S58. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (**12b**) in CDCl₃.



Figure S59. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (**12b**) in CDCl₃.



Figure S60. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (**12b**) in CDCl₃.



Figure S61. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13b**) in CDCl₃.



Figure S62. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13b**) in $CDCI_3$.



Figure S63. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13b**) in $CDCI_3$.



Figure S64. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-3- (methylthio)propyl)phosphonate (**14b**) in $CDCl_3$.



Figure S65. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**) in $CDCl_3$.



Figure S66. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**) in $CDCl_3$.



Figure S67. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**) in $CDCl_3$.



Figure S68. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**) in $CDCI_3$.



Figure S69. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**) in CDCl₃.



Figure S70. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16b**) in CDCl₃.



Figure S71. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16b**) in CDCl₃.



Figure S72. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyimino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16b**) in CDCl₃.



Figure S73. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (**1c**) in $CDCl_3$.



Figure S74. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (1c) in $CDCl_3$.



Figure S75. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (1c) in $CDCl_3$.



Figure S76. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (**2c**) in CDCl₃.



Figure S77. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (**2c**) in CDCl₃.



Figure S78. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (**2c**) in CDCl₃.



Figure S79. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (**3c**) in CDCl₃.



Figure S80. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (3c) in CDCl₃.



Figure S81. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyamino)-2-phenylethyl)phosphonate (3c) in CDCl₃.



Figure S82. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**4c**) in CDCl₃.



Figure S83. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**4c**) in $CDCl_3$.



Figure S84. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**4c**) in CDCl₃.



Figure S85. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**5c**) in CDCl₃.



Figure S86. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (5c) in CDCl₃.



Figure S87. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**5c**) in CDCl₃.



Figure S88. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**6c**) in CDCl₃.


Figure S89. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**6c**) in CDCl₃.



Figure S90. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyamino)-2-methylpropyl)phosphonate (**6c**) in CDCl₃.



Figure S91. ¹H NMR spectrum (400 MHz) of dimethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**7c**) in $CDCI_3$.



Figure S92. ¹³C APT NMR spectrum (100.6 MHz) of dimethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (7c) in $CDCI_3$.



Figure S93. ³¹P NMR spectrum (161.9 MHz) of dimethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**7c**) in $CDCl_3$.



Figure S94. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (8c) in CDCl₃.



Figure S95. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (8c) in $CDCl_3$.



Figure S96. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**8c**) in $CDCI_3$.



Figure S97. ¹H NMR spectrum (400 MHz) of diisopropyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**9c**) in $CDCl_3$.



Figure S98. ¹³C APT NMR spectrum (100.6 MHz) of diisopropyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**9c**) in $CDCI_3$.



Figure S99. ³¹P NMR spectrum (161.9 MHz) of diisopropyl (1-(hydroxyamino)-3-methylbutyl)phosphonate (**9c**) in $CDCI_3$.



Figure S100. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)ethyl)phosphonate (**10c**) in D_2O .



Figure S101. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)ethyl)phosphonate (**10c**) in D_2O .



Figure S102. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)ethyl)phosphonate (**10c**) in D_2O .



Figure S103. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2,2-dimethylpropyl)phosphonate (**11c**) in CDCl₃.



Figure S104. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2,2-dimethylpropyl)phosphonate (**11c**) in $CDCl_3$.



Figure S105. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2,2-dimethylpropyl)phosphonate (**11c**) in $CDCl_3$.



Figure S106. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-methylbutyl)phosphonate (**12c**) in CDCl₃.



Figure S107. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-methylbutyl)phosphonate (**12c**) in CDCl₃.



Figure S108. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-methylbutyl)phosphonate (**12c**) in CDCl₃.



Figure S109. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13c**) in $CDCl_3$.



Figure S110. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13c**) in $CDCl_3$.



Figure S111. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13c**) in $CDCl_3$.



Figure S112. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate (**14c**) in CDCl₃.



Figure S113. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate (**14c**) in $CDCl_3$.



Figure S114. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-3-(methylthio)propyl)phosphonate (**14c**) in $CDCl_3$.



Figure S115. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-(phenylthio)ethyl)phosphonate (**15c**) in $CDCl_3$.



Figure S116. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-(phenylthio)ethyl)phosphonate (**15c**) in $CDCl_3$.



Figure S117. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-(phenylthio)ethyl)phosphonate (**15c**) in $CDCl_3$.



Figure S118. ¹H NMR spectrum (400 MHz) of diethyl (1-(hydroxyamino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16c**) in $CDCl_3$.



Figure S119. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-(hydroxyamino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16c**) in $CDCl_3$.



Figure S120. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-(hydroxyamino)-2-(1*H*-indol-3-yl)ethyl)phosphonate (**16c**) in CDCl₃.



Figure S121. ¹H NMR spectrum (400 MHz) of diethyl (1-amino-2-phenylethyl)phosphonate (**am-2b**) in CDCl₃.



Figure S122. ¹³C APT NMR spectrum (100.6 MHz) of diethyl (1-amino-2-phenylethyl)phosphonate (am-2b) in CDCl₃.



Figure S123. ³¹P NMR spectrum (161.9 MHz) of diethyl (1-amino-2-phenylethyl)phosphonate (**am-2b**) in CDCl₃.

2.5 Copies of IR spectra



Figure S124. Infrared spectrum of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (neat) (2b).



Figure S125. Infrared spectrum of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (neat) (**11b**).







FigureS127.Infraredspectrumofdiethyl(1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (PTyr-OEt) (neat) (13b).



Figure S128. Infrared spectrum of diethyl (1-amino-2-phenylethyl)phosphonate (neat) (am-2b).

2.6 Molecular structure by single crystal X-ray diffraction analysis of compounds 2b and 3b

For the structures of **2b** and **3b**, X-ray intensity data were collected at 100 K, on a Rigaku Oxford Diffraction Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector using ω scans and CuK α (λ = 1.54184 Å) radiation. The images were interpreted and integrated with the program CrysAlisPro.¹⁸ Using Olex2,¹⁹ the structures were solved by direct methods using the ShelXS/T structure solution programs and refined by full-matrix least-squares on F² using the ShelXL program package.^{20,21} Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in the riding mode with isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times for methyl and hydroxyl groups). Hydroxyl hydrogen atoms were located from a difference Fourier electron density map.

Crystal data for compound **2b.** $C_{12}H_{18}NO_4P$, M = 271.24, monoclinic, space group $P2_1/n$ (No. 14), a = 10.6343(2) Å, b = 6.96240(10) Å, c = 18.1231(3) Å, $B = 91.140(2)^\circ$, V = 1341.57(4) Å³, Z = 4, T = 100(1) K, $\rho_{calc} = 1.343$ g cm⁻³, μ (Cu-K α) = 1.896 mm⁻¹, 24185 reflections measured (9.56° $\leq 2\Theta \leq 150.418^\circ$), 2755 unique ($R_{int} = 0.0648$, $R_{sigma} = 0.0300$) which were used in all calculations. The final R1 was 0.0386 ($I > 2\sigma$ (I)) and wR2 was 0.1095 (all data). The structure was refined as a mixture of two isomers with respect to the oxime C=N double bound (E/Z, 67:33) both isomers are present in the crystal structure.

Crystal data for compound **3b**. C₁₄H₂₂NO₄P, *M* = 299.30, monoclinic, space group *P*2₁/c (no. 14), *a* = 17.0855(2) Å, *b* = 8.08470(10) Å, *c* = 11.59340(10) Å, *b* = 96.2960(10)°, *V* = 1591.75(3) Å³, *Z* = 4, *T* = 100(1) K, ρ_{calc} = 1.249 g cm⁻³, μ (Cu-Kα) = 1.644 mm⁻¹, 28966 reflections measured (5.204° ≤ 2Θ ≤ 147.924°), 3197 unique (R_{int} = 0.0432, R_{sigma} = 0.0198) which were used in all calculations. The final *R*1 was 0.0339 (*I* >2 σ (*I*)) and *wR*2 was 0.0923 (all data). Only the *E* isomer with respect to the oxime C=N double bound is present in the crystal structure.

CCDC 2115990-2115991 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/structures</u>.



S129. Asymmetric unit of the crystal structure of (*2b*), showing thermal displacement ellipsoids at the 50% probability level. The structure highlights the presence of both isomers with respect to the oxime C=N double bound (E = blue + red, Z = yellow).



Figure S130. Asymmetric unit of the crystal structure of *(3b)*, showing thermal displacement ellipsoids at the 50% probability level. The structure highlights the presence of only the *E* isomer with respect to the oxime C=N double bound.

3 Collision energy breakdown curves and survival yields

The structures of the main fragments for each breakdown curve have been identified and summarized in Table S2.





Figure S131. Breakdown curve of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1b, Z_{iso}).



Figure S132. Breakdown curve of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1b, E_{iso}).



Figure S133. Breakdown curve of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1b, Mix).



Figure S134. Survival yield of dimethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (1b).



3.2 Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b)

Figure S135. Breakdown curve of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b, Z_{iso}).



Figure S136. Breakdown curve of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b, Eiso).



Figure S137. Breakdown curve of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b, Mix).



Figure S138. Survival yield of diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (2b).



3.3 Diethyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3b)

Figure S139. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3b, Z_{iso}).



Figure S140. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3b, E_{iso}).



Figure S141. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (**3b**, **Mix**).



Figure S142. Survival yield of diisopropyl (1-(hydroxyimino)-2-phenylethyl)phosphonate (3b).



3.4 Dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (4b)

Figure S143. Breakdown curve of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (4b, Z_{iso}).



Figure S144. Breakdown curve of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**4b**, **E**_{iso}).



Figure S145. Breakdown curve of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (4b, Mix).



Figure S146. Survival yield of dimethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (4b).



3.5 Diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b)

Figure S147. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b, Z_{iso}).



Figure S148. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b, E_{iso}).



Figure S149. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b, Mix).



Figure S150. Survival yield of diethyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (5b).



3.6 Diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (6b)

Figure S151. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (6b, Z_{iso}).



Figure S152. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**6b**, **E**_{iso}).



Figure S153. Breakdown curve of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (**6b**, **Mix**).



Figure S154. Survival yield of diisopropyl (1-(hydroxyimino)-2-methylpropyl)phosphonate (6b).



3.7 Dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b)

Figure S155. Breakdown curve of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b, Z_{iso}).



Figure S156. Breakdown curve of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b, E_{iso}).


Figure S157. Breakdown curve of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b, Mix).



Figure S158. Survival yield of dimethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (7b).



3.8 Diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b)

Figure S159. Breakdown curve of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b, Z_{iso}).



Figure S160. Breakdown curve of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b, Eiso).



Figure S161. Breakdown curve of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b, Mix).



Figure S162. Survival yield of diethyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (8b).



3.9 Diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (9b)

Figure S163. Breakdown curve of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (9b, Z_{iso}).



Figure S164. Breakdown curve of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (**9b**, **E**_{iso}).



Figure S165. Breakdown curve of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (9b, Mix).



Figure S166. Survival yield of diisopropyl (1-(hydroxyimino)-3-methylbutyl)phosphonate (9b).



3.10 Diethyl (1-(hydroxyimino)ethyl)phosphonate (10b)

Figure S167. Breakdown curve of diethyl (1-(hydroxyimino)ethyl)phosphonate (10b, E_{iso}).



Figure S168. Survival yield of diethyl (1-(hydroxyimino)ethyl)phosphonate (10b).



3.11 Diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (11b)

Figure S169. Breakdown curve of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**, **Z**_{iso}).



Figure S170. Breakdown curve of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**, **E**_{iso}).



Figure S171. Breakdown curve of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (**11b**, **Mix**).



Figure S172. Survival yield of diethyl (1-(hydroxyimino)-2,2-dimethylpropyl)phosphonate (11b).



3.12 Diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b)

Figure S173. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b, Z_{iso}).



Figure S174. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b, Eiso).



Figure S175. Breakdown curve of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b, Mix).



Figure S176. Survival yield of diethyl (1-(hydroxyimino)-2-methylbutyl)phosphonate (12b).



(1-(hydroxyimino)-2-(4-

3.13 Diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (13b)

Figure\$\$177.Breakdowncurveofdiethylmethoxyphenyl)ethyl)phosphonate (13b, Z_{iso}).



methoxyphenyl)ethyl)phosphonate (**13b, E**_{iso}).



Figure\$179.Breakdowncurveofdiethyl(1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (13b, Mix).



Figure S180. Survival yield of diethyl (1-(hydroxyimino)-2-(4-methoxyphenyl)ethyl)phosphonate (**13b**).



3.14 Diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (14b)

Figure S181. Breakdown curve of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**, **Z**_{iso}).



Figure S182. Breakdown curve of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**, **E**_{iso}).



Figure S183. Breakdown curve of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (**14b**, **Mix**).



Figure S184. Survival yield of diethyl (1-(hydroxyimino)-3-(methylthio)propyl)phosphonate (14b).



3.15 Diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (15b)

Figure S185. Breakdown curve of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**, **Z**_{iso}).



Figure S186. Breakdown curve of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**, **E**_{iso}).



Figure S187. Breakdown curve of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (**15b**, **Mix**).



Figure S188. Survival yield of diethyl (1-(hydroxyimino)-2-(phenylthio)ethyl)phosphonate (15b).



3.16 Diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (16b)

Figure S189. Breakdown curve of diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (**16b**, **Z**_{iso}).



Figure S190. Breakdown curve of diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (**16b**, **E**_{iso}).



Figure S191. Breakdown curve of diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (**16b**, **Mix**).



Figure S192. Survival yield of diethyl (1-(hydroxyimino)-2-(1H-indol-3-yl)ethyl)phosphonate (16b).

Compound	Structure	Fragment 1	Fragment 2	Fragment 3	Fragment 4	Fragment 5
1b (Z _{iso})	O W O Me O Me O O O Me O O O O Me O O O Me O O Me O Me O Me N O Me Me O Me N O Me Me O Me N O Me N O Me N O Me Me O Me N O Me Me N O Me N O Me Me N O Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me N O Me Me Me Me Me Me Me Me Me Me	+0 ^{-H} ^{II} -OMe HO ^{-P} ⁻ OMe C ₂ H ₈ O ₄ P ⁺ MW 127,0155	MW 109.0088	C ₇ H ₇ ⁺ MW 91,0542		
1b (E _{iso})	OMe POMe HO ^N C ₁₀ H ₁₄ NO ₄ P MW 243,20	+0 ^{−H} ^{II} _− OMe HO ^{−P} OMe C ₂ H ₈ O ₄ P ⁺ MW 127,0155	MW 109.0088	C ₇ H ₇ ⁺ MW 91,0542		
2b (Z _{iso})	O H OEt N OH C ₁₂ H ₁₈ NO ₄ P MW 271,25	+O ⁺ H "OEt HO ⁺ OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	+O ⁺ H HO ⁺ OH HO ⁺ OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	+O, H	C ₇ H ₇ ⁺ MW 91,0542	
2b (<i>E</i> _{iso})	O HO ^N C ₁₂ H ₁₈ NO ₄ P MW 271,25	+0,-H ,,OH ,OEt HO'N C ₁₀ H ₁₅ NO ₄ P ⁺ MW 244,0733	+0 ⁺ H ,OH ,OH HO ⁻ N C ₈ H ₁₁ NO ₄ P ⁺ MW 216,0420	C ₇ H ₂ ⁺ C ₇ H ₇ ⁺ MW 91,0542		

Table S2. Summary of the major fragments observed in MS for each isomer

3b (Z _{iso})	O ^I Pr P ⁻ O ⁱ Pr N O ^I Pr O ⁱ Pr N O ^I Pr MW 299,31	O P O ⁱ Pr O ⁱ Pr H ⁺ OH C ₁₁ H ₁₇ NO ₄ P ⁺ MW 258,0890	O H H H H H H H H H H H H H H H H H H H	+O, H	C7H7 ⁺ MW 91,0542	
3b (E _{iso})	O P O ⁱ Pr O ⁱ Pr O ⁱ Pr O ⁱ Pr O ⁱ Pr O ⁱ Pr O ⁱ Pr MO ⁱ N O ⁱ Pr	+0 ⁺ H ,OH PO ⁱ Pr HO ⁻ N C ₁₁ H ₁₇ NO ₄ P ⁺ MW 258,0890	+0, ^H ,,OH ,,OH ,OH ,OH ,OH ,OH ,OH ,OH ,OH ,	C ₇ H ₇ ⁺ MW 91,0542		
4b (Z _{iso})	O	+o ^{-H} "-OMe HO ^{-P} ⁻ OMe C ₂ H ₈ O ₄ P⁺ MW 127,0155	MW 109.0095			
4b (E _{iso})	O HO ^N C ₆ H ₁₄ NO ₄ P MW 195,15	OMe POMe N ⁺ C ₆ H ₁₃ NO ₃ P ⁺ MW 178,0628	+O ⁺ H "-OMe HO ⁺ ⁻ OMe C ₂ H ₈ O ₄ P⁺ MW 127,0155	MW 109.0095		
5b (Z _{iso})	O H OEt N OH C ₈ H ₁₈ NO ₄ P MW 223,21	+O ⁺ H "OEt HO ^{-P} OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	+0 ⁺ H #OH HO ⁺ OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	+O ⁺ H ⁺ OH HO ⁺ OH H ₄ O ₄ P ⁺ MW 98,9842		

5b (<i>E</i> _{iso})	O HO ^{-N} C ₈ H ₁₈ NO ₄ P MW 223,21	$\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & &$	$ \begin{array}{c} +0^{-}H \\ +0^{-}H \\ +0^{-}OH \\ -0^{-}OH \\ H0^{-}N \\ C_{4}H_{11}NO_{4}P^{+} \\ MW 168,0420 \\ \end{array} $			
6b (Z _{iso})	O H O ⁱ Pr P O ⁱ Pr N OH C ₁₀ H ₂₂ NO ₄ P MW 251,26	O H ⁺ O ⁱ Pr H ⁺ OH C ₇ H ₁₇ NO ₄ P ⁺ MW 210,0890	0	O ↓ O H OH OH OH OH OH OH OH OH	⁺ O [−] H OH HO ^{−P} [−] OH H ₄ O ₄ P ⁺ MW 98,9842	
6b (E _{iso})	O H O ⁱ Pr O ⁱ Pr HO ^N C ₁₀ H ₂₂ NO ₄ P MW 251,26	+0 ⁻ H HO ⁻ N C ₇ H ₁₇ NO ₄ P ⁺ MW 210,0890	+0 ⁺ H HO ⁺ OH HO ⁻ N C ₄ H ₁₁ NO ₄ P ⁺ MW 168,0420			
7b (Z _{iso})	O H OMe P OMe N OH C ₇ H ₁₆ NO ₄ P MW 209,18	+o ^{∠H} "∠OMe HO ^{/P} [×] OMe C ₂ H ₈ O ₄ P⁺ MW 127,0155	MW 109.0057			
7b (<i>E</i> _{iso})	O #_OMe P OMe HO ⁻ N C ₇ H ₁₆ NO ₄ P MW 209,18	O H O Me O O O Me O O O O O O O O O O O O O	+0 ^{-H} "-OMe HO ^{-P} ⁻ OMe C ₂ H ₈ O ₄ P⁺ MW 127,0155	MW 109.0057		

8b (Z _{iso})	OEt P-OEt N OH C ₉ H ₂₀ NO ₄ P MW 237,24	+ _O ∽ ^H ",OEt HO ^{~P} OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	+ _O ∠H ^{II} ∠OH HO ^{2 ™} OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	+ _O ,H	
8b (E _{iso})	OEt POEt HO C ₉ H ₂₀ NO ₄ P MW 237,24	+0 ^{-H} ,OH ,OEt HO ⁻ C ₇ H ₁₇ NO ₄ P ⁺ MW 210,0890	+0, ^H HOH HO ^N C ₅ H ₁₃ NO ₄ P ⁺ MW 182,0577		
9b (Z _{iso})	O H-O ⁱ Pr O ⁱ Pr N OH C ₁₁ H ₂₄ NO ₄ P MW 265,29	O H ^P →O ⁱ Pr H ^P →O ⁱ Pr H ^P →OH C ₈ H ₁₉ NO ₄ P ⁺ MW 224,1046	O ↓ OH P OH H N OH H OH C ₅ H ₁₃ NO ₄ P ⁺ MW 182,0577	+O ⁺ H [₩] OH HO ⁺ OH H ₄ O ₄ P ⁺ MW 98,9842	
9b (E _{iso})	O P O ⁱ Pr O ⁱ Pr HO ⁻ C ₁₁ H ₂₄ NO ₄ P MW 265,29	+0 ⁻ H HOH HO ⁻ N C ₈ H ₁₉ NO ₄ P ⁺ MW 224,1046	+0, H #, OH P OH HO'N C ₅ H ₁₃ NO ₄ P ⁺ MW 182,0577		
10b (<i>E</i> _{iso})	OEt POEt HO ^N C ₆ H ₁₄ NO ₄ P MW 195,15	+0, ^H ,OH ,OEt HO ^N C ₄ H ₁₁ NO ₄ P ⁺ MW 168,0420	+0-H "-OH "-OH HO ^{-N} C ₂ H ₇ NO ₄ P ⁺ MW 140,0107		

11b (Z _{iso})	O U O O O O O O O O O O O O O	+ _O -H "-OEt HO ^{-P} OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	+ _O ,H ,,OH HO ^{, P} [×] OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	+ _O ,H II,OH HO ^{, P} ,OH H ₄ O ₄ P+ MW 98,9842		
11b (<i>E</i> _{iso})	HO ^{-N} C ₉ H ₂₀ NO ₄ P MW 237,24	+0 ⁻ H ,OH P-OEt HO ⁻ N C ₇ H ₁₇ NO ₄ P ⁺ MW 210,0890	$+0^{+}H$ $+0^{+}H$ $+0^{+}OH$ $P^{+}OH$ $H0^{-}N$ $C_{5}H_{13}NO_{4}P^{+}$ MW 182,0577	O H O H O O O O O O O O O O H O O H H H H H H H H H H H H H		
12b (Z _{iso})	O H O O E V O E V O E V O E t O E t O E t O E t O E t O E t O E t O E t O E t N O E t N O E t O E t	+0 ⁺ H #OEt HO ⁺ OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	⁺ O ⁺ H ^H OH HO ⁺ OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	⁺ O ⁻ H OH HO ⁻ P ⁻ OH H₄O₄P ⁺ MW 98,9842		
12b (<i>E</i> _{iso})	OEt HO ^{-N} C ₉ H ₂₀ NO ₄ P MW 237,24	+0, ^H HOH DEt HO ⁻ N C ₇ H ₁₇ NO ₄ P ⁺ MW 210,0890	+0 ⁺ H HO ⁺ OH HO ⁺			
13b (Z _{iso})	MeO C ₁₃ H ₂₀ NO ₅ P MW 301,28	+O ⁺ H "-OEt HO ⁺ OEt C ₄ H ₁₂ O ₄ P ⁺ MW 155,0468	+O ⁺ H "-OH HO ⁺ OEt C ₂ H ₈ O ₄ P ⁺ MW 127,0155	MeO C ₈ H ₉ O ⁺ MW 121,0648	+O ⁺ H ^{II} ,OH HO ⁻ P ⁺ OH H₄O₄P ⁺ MW 98,9842	

13b (E _{iso})	MeO C ₁₃ H ₂₀ NO ₅ P MW 301,28	HO ^{+O} ^{+H} HO ⁺ OEt HO ⁻ N C ₁₁ H ₁₇ NO ₅ P ⁺ MW 274,0839	+ _O , ^H [#] OH ^P OH HO ⁻ N C ₉ H ₁₃ NO ₅ P ⁺ MW 246,0526	MeO C ₈ H ₉ O ⁺ MW 121,0648		
14b (Z _{iso})	S N O H O O O O O O O O O O O O O	S C ₈ H ₁₇ NO ₃ PS ⁺ MW 238,0661	S → C ₆ H ₁₃ NO ₃ PS ⁺ MW 210,0348	MW 109.0096	MW 80.9766	∑S_CH ₂ ⁺ C ₃ H ₇ S ⁺ MW 75,0263
14b (E _{iso})	S HO ^N C ₈ H ₁₈ NO ₄ PS MW 255,27	S C ₈ H ₁₇ NO ₃ PS ⁺ MW 238,0661	S → C ₆ H ₁₃ NO ₃ PS ⁺ MW 210,0348	MW 109.0096	MW 80.9766	
15b (Z _{iso})	O H O O O O O O O O O O O O O	C ₁₂ H ₁₇ NO ₃ PS ⁺ MW 286,0661	C ₁₀ H ₁₃ NO ₃ PS ⁺ MW 258,0348	C ₈ H ₉ NO ₃ PS ⁺ MW 230,0035	C ₇ H ₇ S ⁺ MW 123,0263	
15b (E _{iso})	O S I HO ['] N C ₁₂ H ₁₈ NO ₄ PS MW 303,31	C ₁₂ H ₁₇ NO ₃ PS ⁺ MW 286,0661	C ₁₀ H ₁₃ NO ₃ PS ⁺ MW 258,0348	C ₈ H ₉ NO ₃ PS ⁺ MW 230,0035	C ₇ H ₇ S ⁺ MW 123,0263	C ₆ H ₅ S ⁺ MW 109,0106

16b (Z _{iso})	HN HN HN HN H C ₁₄ H ₁₉ N ₂ O ₄ P MW 310,29	$H_{CH_2^+}$ $C_9H_8N^+$ MW 130,1695		
16b (<i>E</i> iso)	O HN HO C ₁₄ H ₁₉ N ₂ O ₄ P MW 310,29	$C_{9}H_{8}N^{+}$ MW 130,1695		

4 Computational study

4.1 Oxime isomers

4.1.1 Protonation site with regards to the isomers

Favorable protonation site calculations on 9 couple of oxime isomers (i.e. **1b-9b**) have been performed with Gaussian 09 (version D.01) by DFT at the B3LYP/6-31G(d) level of theory.²² Each isomer exhibits two stable protonation sites: one in the amine moiety (-N-H⁺) and the other on the phosphonate moiety (-P=O-H⁺). Enthalpy, entropy and free enthalpy variations at 298.15K ($\Delta H^{\circ}_{298.15K}$, $\Delta S^{\circ}_{298.15K}$, and $\Delta G^{\circ}_{298.15K}$, respectively) of the -N-H⁺ \rightleftharpoons -P=O-H⁺ reaction (proton transfer) are reported in Table S3. A negative value of $\Delta G^{\circ}_{298.15K}$ indicates that -P=O-H⁺ is more stable than -N-H⁺. Inversely, a positive value of $\Delta G^{\circ}_{298.15K}$ indicates that -N-H⁺ is more stable than -P=O-H⁺. The calculated $\Delta G^{\circ}_{298.15K}$ values support that the phosphonate moiety is the more favorable protonation site for *E* isomers while protonation occurs preferentially on the amino moiety for *Z* isomers. These calculations are in good agreement with the experimental observations done by ion mobility mass spectrometry.

Table S3 : Calculated enthalpy, entropy and free enthalpy variations at 298.15K ($\Delta H^{\circ}_{298.15K}$, $\Delta S^{\circ}_{298.15K}$, and $\Delta G^{\circ}_{298.15K}$, respectively) for the proton transfer reaction from the amino moiety (reactant) to the phosphonate moiety (product) of investigated oxime isomers, -N-H⁺ \rightleftharpoons -P=O-H⁺.

		-N·	·H⁺ ≓ -Р=О-Н	+
Compound	Isomer			
		ΔH° _{298.15K}	ΔS° _{298.15K}	ΔG° _{29815K}
1b	Ε	-10.21	-7.78	-7.89
	Ζ	70.58	11.78	67.07
2b	Ε	-14.27	-5.07	-12.75
	Ζ	53.71	-11.94	57.27
3b	Ε	-18.58	6.11	-20.40
	Ζ	8.02	-5.79	9.74
4b	Е	-20.86	-14.69	-16.48
	Ζ	6.95	4.84	5.51
5b	Е	-14.44	-7.35	-12.25
	Ζ	71.98	22.29	65.34
6b	Е	-24.96	-7.70	-22.67
	Ζ	69.26	47.58	55.07
7b	Е	-17.37	-2.71	-16.56
	Ζ	81.18	23.05	74.30
8b	Е	-22.61	4.63	-23.99
	Ζ	74.88	21.52	68.47
9b	Е	-36.08	-8.05	-33.68
	Ζ	64.52	13.59	60.46

5 References

- D. E. Bierer, L. G. Dubenko, P. Zhang, Q. Lu, P. A. Imbach, A. W. Garofalo, P. W. Phuan, D. M. Fort,
 J. Litvak, R. E. Gerber, B. Sloan, J. Luo, R. Cooper and G. M. Reaven, *J. Med. Chem.*, 1998, 41, 2754–2764.
- 2 J. L. Viveros-Ceballos, F. J. Sayago, C. Cativiela and M. Ordóñez, *European J. Org. Chem.*, 2015, 2015, 1084–1091.
- Z. Hassen, A. Ben Akacha and H. Zantour, *Phosphorus, Sulfur Silicon Relat. Elem.*, 2003, **178**, 2241–2253.
- 4 E. Migianu, E. Guénin and M. Lecouvey, *Synlett*, 2005, **2005**, 425–428.
- 5 C. C. Tam, K. L. Mattocks and M. Tishler, *Proc. Natl. Acad. Sci.*, 1981, **78**, 3301–3304.
- D. Shen, K. Hensley and T. T. Denton, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 562–565.
- 7 K. Hensley, T. Denton. (2017). *Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same* (US/Toledo Patent No. 11,084,836). U.S. Patent and Trademark Office. https://rb.gy/ik0fb0
- 8 A. Ryglowski and P. Kafarski, *Synth. Commun.*, 1994, **24**, 2725–2731.
- 9 J. L. Viveros-Ceballos, M. Ordóñez, F. J. Sayago, A. I. Jiménez and C. Cativiela, *European J. Org. Chem.*, 2016, 2016, 2711–2719.
- 10 J. Kowalik, L. Kupczyk-Subotkowska and P. Mastalerz, *Synthesis (Stuttg).*, 1981, **1981**, 57–58.
- 11 J.-L. Clément, C. Fréjaville and P. Tordo, *Res. Chem. Intermed.*, 2002, **28**, 175–190.
- 12 B. Krzyzanowska and S. Pilichowska, *Pol. J. Chem.*, 1988, **62**, 165–177.
- 13 L. Maier and P. J. Diel, *Phosphorus. Sulfur. Silicon Relat. Elem.*, 1991, **62**, 15–27.
- 14 C. Yuan, S. Chen, H. Zhou and L. Maier, *Synthesis (Stuttg).*, 1993, **1993**, 955–957.
- 15 A. Heydari, M. Mehrdad and H. Tavakol, *Synthesis (Stuttg).*, 2003, 2003, 1962–1964.
- 16 R. Huber and A. Vasella, *Helv. Chim. Acta*, 1987, **70**, 1461–1476.
- 17 A. Nudelman, Y. Bechor, E. Falb, B. Fischer, B. A. Wexler and A. Nudelman, *Synth. Commun.*, 1998, **28**, 471–474.
- 18 Rigaku Oxford Diffraction, 2019, CrysAlisPro Software system, version 1.171.40.53, Rigaku Corporation, Oxford, UK.
- 19 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann and IUCr, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 20 G. M. Sheldrick, *Acta Crystallogr. Sect. A Found. Crystallogr.*, 2015, **71**, 3–8.
- G. M. Sheldrick and IUCr, Acta Crystallogr. Sect. C Struct. Chem., 2015, 71, 3–8.
- Gaussian 09, Revision D.01, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J.

J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford CT, 2009